Поиск патентов

Настройки

Глубина выборки

Укажите год

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Ключевые слова. Может быть несколько по одной на строку

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка

Автор

Ведите корректный номера.

Владелец

Ведите корректный номера.

Классы IPC

Ведите корректный номера.

Классы CPC

Ведите корректный номера.

Начиная с года

Укажите год

Заканчивая годом

Укажите год

Применить Всего найдено 22170. Отображено 100.

05-01-2012 дата публикации

Dispersion composition and method for manufacturing dispersion composition

Номер: US20120003288A1

Автор: Hisahiro Mori

Принадлежит: Fujifilm Corp

The present invention provides: a dispersion composition including a poorly water-soluble polyphenol compound, an emulsifier including a sucrose fatty acid ester, and a water-soluble polymer, in which a content of a polyglycerin fatty acid ester in the composition is 0, or 0.1 or fewer times a total mass of the sucrose fatty acid ester in the composition, and a particle size of the dispersed particles including the poorly water-soluble polyphenol is 200 nm or smaller; and a method for manufacturing the dispersion composition, the method including an oil phase preparation process in which an oil phase is prepared by dissolving one or more oil phase components including the poorly water-soluble polyphenol in a good solvent for the poorly water-soluble polyphenol compound, and a mixing process in which the obtained oil phase and a phase of a poor solvent for the poorly water-soluble polyphenol compound are mixed to obtain the dispersion composition which includes the poorly water-soluble polyphenol compound and includes dispersed particles having an average volume particle size of 200 nm or smaller.

Подробнее

Номер записи: 1

19-01-2012 дата публикации

Enhanced Natural Colors

Номер: US20120014934A1

Автор: Jeffrey M. Wuagneux, Paul Altaffer, Pi-Yu Hsu

Принадлежит: RFI LLC

A natural color is concentrated to intensify color range and to provide useful amounts of one or more of anti-oxidant, nutritional, and anti-inflammatory compounds derived from one or more pigment sources. In a preferred embodiment, the pigment source is a fruit, a vegetable, a legume, a spice, algae, or a combination thereof.

Подробнее

Номер записи: 2

02-02-2012 дата публикации

Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications

Номер: US20120028922A1

Автор: Fotini Sampalis

Принадлежит: Individual

A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

Подробнее

Номер записи: 3

02-02-2012 дата публикации

Compositions for treating or preventing obesity and insulin resistance disorders

Номер: US20120029065A1

Автор: David A. Sinclair, Maria Alexander-Bridges

Принадлежит: General Hospital Corp, Harvard College

Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.

Подробнее

Номер записи: 4

02-02-2012 дата публикации

Compositions and methods for treating or preventing radiation injury

Номер: US20120029071A1

Автор: Rajesh K. Thimmulappa, Shyam Biswal

Принадлежит: JOHNS HOPKINS UNIVERSITY

The invention provides compositions and methods featuring Nrf2 activators for treating or preventing radiation-associated tissue damage.

Подробнее

Номер записи: 5

02-02-2012 дата публикации

Anti-anxiety composition

Номер: US20120029088A1

Автор: Atsushi OOYAGI, Hideaki Hara, Takashi Ishibashi

Принадлежит: JX Nippon Oil and Energy Corp

This invention provides a highly safe anti-anxiety composition that can be used for treatment or prevention of anxiety disorders. Such anti-anxiety composition comprises, as an active ingredient, a carotenoid.

Подробнее

Номер записи: 6

01-03-2012 дата публикации

Inhibition of undesired sensory effects by the compound camphor

Номер: US20120052021A1

Автор: Diana McKinney, Gerd Kobal, Maria Gogova, Prasad Babu Deenadayalan Polur

Принадлежит: PHILIP MORRIS USA INC

A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.

Подробнее

Номер записи: 7

08-03-2012 дата публикации

Pharmaceutical compositions and methods for treating tuberculosis

Номер: US20120058977A1

Автор: Lubbert Dijkhuizen, Martin Ostendorf, Peter Van Der Meijden, Robert Van Der Geize

Принадлежит: Rijksuniversiteit Groningen

A pharmaceutical composition for the treatment of a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes, said composition comprising an effective amount of a compound selected from compound I, (+)-compound II, (−)-compound II, compound III, or mixtures thereof.

Подробнее

Номер записи: 8

26-04-2012 дата публикации

Anti-Emetic Substance

Номер: US20120101089A1

Автор: Ankit Bharat, Ashwani Agarwal

Принадлежит: Individual

The present invention provides a therapeutic solution for effective control of symptoms related to nausea and vomiting. The therapeutic solution is a pharmaceutical composition which combines anti-emetics of different classes. These classes include dopamine receptor antagonists, serotonin receptor antagonists, butyrphenones, and neurokinin receptor antagonists. The combination of different anti-emetics mitigates adverse affects of a single anti-emetic alone while increasing drug efficacy and decreasing cost of administration to the individual patient.

Подробнее

Номер записи: 9

26-04-2012 дата публикации

Methods of providing anticoagulation effects in subjects

Номер: US20120101169A1

Автор: Amale Hawi

Принадлежит: Penwest Pharmaceuticals Co

The present invention is directed to methods of providing anticoagulation effects in subjects in need thereof, comprising administering to the subjects at least twice a day compounds of the present invention, stereoisomers, and racemates thereof.

Подробнее

Номер записи: 10

17-05-2012 дата публикации

Terpene Glycosides and Their Combinations as Solubilizing Agents

Номер: US20120121696A1

Автор: Zhijun Liu

Принадлежит: Louisiana State University and Agricultural and Mechanical College

Several terpene glycosides (e.g., mogroside V, paenoiflorin, geniposide, rubusoside, rebaudioside A, steviol mono-side and stevioside) were discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including but not limited to, paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole, celecoxib, clofazimine, digoxin, oleandrin, nifedipine, and amiodarone. The use of the diterpene glycoside rubusoside and monoterpene glycoside paenoiflorin increased solubility in all tested compounds. The terpene glycosides are a naturally occurring class of water solubility-enhancing compounds that are non-toxic and that will be useful as new complexing agents or excipients in the pharmaceutical, agricultural (e.g., solubilizing pesticides), cosmetic and food industries.

Подробнее

Номер записи: 11

17-05-2012 дата публикации

Combination of curcuminoids and mtor inhibitors for the treatment of tauopathies

Номер: US20120122913A1

Автор: Guylaine Lassonde, Michel Charbonneau

Принадлежит: Institut National de La Recherche Scientifique INRS

Methods, uses, compositions, combinations and kits relating to the decrease of Tau protein levels, and prevention and/or treatment of diseases or disorders associated with Tau protein (Tauophathies), such as Alzheimer's disease, using a curcuminoid and a mammalian target rapamycin (mTOR) inhibitor, are described.

Подробнее

Номер записи: 12

31-05-2012 дата публикации

Topical Compositions Comprising An Alkoxylated Diphenylacrylate Compound And An Aryl Carboxylic Ester

Номер: US20120134943A1

Автор: Ismail Ahmed Syed, Linda Josephine Najdek, Milanka Susak, Mirela Cristina Ionita-Manzatu

Принадлежит: ELC Management LLC

A topical composition containing an alkoxylated diphenylacrylate compound and an aryl carboxylic ester is provided. Preferably, the topical composition is a sunscreen composition containing α-ethylhexyl α-cyano-β-(4-methoxyphenyl)-β-phenylacrylate and 2-phenylethyl benzoate, and optionally further containing 4,4′-t-butyl methoxydibenzoylmethane, which is characterized by improved photo-protection of the skin and is effective in preventing/reducing photo-damage of the skin upon exposure to sunlight or other sources of light in the ultraviolet (UV), visible, and infrared (IR) ranges.

Подробнее

Номер записи: 13

31-05-2012 дата публикации

Liposome-encapsulated glutathione for oral administration

Номер: US20120135068A1

Автор: Brian C. Keller, F. Timothy Guilford

Принадлежит: Your Energy Systems LLC

The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.

Подробнее

Номер записи: 14

31-05-2012 дата публикации

Fatty acids as anti-inflammatory agents

Номер: US20120136034A1

Автор: Bruce A. Freeman, Francisco J. Schopfer

Принадлежит: University of Pittsburgh

Compounds of formula I and their metabolites are potent mediators of an inflammatory response: (I) where a, b, c, d, e, f, V, W, X, Y, R a , R a′ , R b , R b′ , R c , and R c′ are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.

Подробнее

Номер записи: 15

31-05-2012 дата публикации

Ameliorant for renal insufficiency

Номер: US20120136068A1

Автор: Bang Luu, Hiroto Suzuki, Keisuke Sato, Masashi Yamada, Motoaki Saito

Принадлежит: Meiji Co Ltd

The present invention relates to an agent for improving renal dysfunction comprising as an active ingredient a compound represented by the following formula (1): wherein each R 1 , R 2 , and R 3 represents a hydrogen atom or a methyl group, and X represents a linear or branched alkylene or alkenylene group having 10 to 28 carbon atoms.

Подробнее

Номер записи: 16

07-06-2012 дата публикации

Nutritional supplement

Номер: US20120141447A1

Автор: Ford D. Albritton, Iv

Принадлежит: Individual

A nutritional supplement for inhibiting sensorineural hearing loss includes from about 0.25 to about 6.0 wt. % thiamin, from about 0.1 to about 10 wt. % pyridoxiyl-5-phosphate, from about 0.01 to about 10 wt. % folic acid, from about 0.025 to about 4.0 wt. % hydroxycobalamin, from about 1 to about 7 wt. % magnesium, from about 0.25 to about 6.0 wt. % zinc, from about 0.001 to about 0.02 wt. % selenium, from about 0.1 to about 10 wt. % manganese, from about 5 to about 50 wt. % ginger root P.E. 4:1., from about 5 to about 40 wt. % citrus bioflavonoids, from about 2.5 to about 40 wt. % 1-cystine, from about 5 to about 40 wt. % n-acetlyl-1-carnitine, from about 1 to about 40 wt. % alpha lipoic acid, from about 1 to about 40 wt. % coenzyme Q10, from about 1 to about 40 wt. % green tea extract, and from about 1 to about 60 wt. % resveratrol.

Подробнее

Номер записи: 17

14-06-2012 дата публикации

Use of jasmonate to treat bladder dysfunction

Номер: US20120149655A1

Автор: Brunde Broady

Принадлежит: Broady Health Sciences LLC

A formulation or composition contractility comprising jasmonate for modulating bladder and/or treating bladder dysfunction, particularly an overactive bladder in a mammal, particularly a human and use of jasmonate for treating bladder dysfunction is provided.

Подробнее

Номер записи: 18

21-06-2012 дата публикации

Combination therapy for cancer comprising a platinum-based antineoplastic agent and a biocompatible electron donor

Номер: US20120156311A1

Автор: Qing-bin LU

Принадлежит: Individual

The combination of a biocompatible electron donor and a platinum-based antineoplastic agent exhibits improved efficacy in treating cancer This improved activity appears to be the result of electron transfer from the aforementioned donor compound to the platinum-based antineoplastic agent As the electron donor alone has no chemotherapeutic utility in treating cancer, the resulting combinations appear to be synergistic in nature In select preferred embodiments, the biocompatible electron donor is an amine (such as N,N,N′,N′-tetramethyl-p-phenylene diamine or indocyanine green), a phenolic compound (such as a flavanol or catechin), or a quinone (such as an aromatic quinone), while the antineoplastic is cisplatin.

Подробнее

Номер записи: 19

21-06-2012 дата публикации

Compositions and applications of carotenoids of improved absorption and bioavailability

Номер: US20120157547A1

Автор: José-Odon Torres-Quiroga, Ricardo Montoya-Olvera

Принадлежит: Industrial Organica de C V SA

Micro micellar form of carotenoids or xanthophylls, which show improved absorption and biovailability by living organisms, providing higher levels of carotenoids in the blood stream, and consequently are deposited at the target tissues at a faster rate, and more efficiently than crystalline carotenoids, which does not contain any crystal forms of carotenoids, and which are obtained as micro micelles after melting Lutein diacetate or Lutein dipropionate in their natural original lipid vegetable matrix, in the presence of lipids, phospholipids, fatty acids, emulsifiers and moisture, and are ingested in a dosage between 2 to 50 mg, to provide an absorption of the carotenoid solubilizate which is at least 20% above than that of crystalline carotenoids, and provides a macular pigment deposit which exceeds at least 10% of Macular Pigment Optical Density, than the deposition obtained by ingesting crystalline Lutein. Thus preventing tissue degeneration, UV light damage to skin and the retina, and in general to act as more effective and efficient antioxidants than when administered in crystalline form.

Подробнее

Номер записи: 20

28-06-2012 дата публикации

Chinese herbal medicine composition used for antiinflammation, detumescence and acesodyne, and preparation method and use thereof

Номер: US20120164249A1

Автор: Tai-Ting Chou, Tian Shung Wu

Принадлежит: Uni President Biotech Co Ltd

A Chinese herbal medicine composition used for antiinflammation, detumescence and acesodyne, comprising first type of medicinal materials and second type of medicinal materials. The first type of medicinal materials include Rhizoma Bletillae, Cortex Cinnamomi, Radix Angelicae Formosanae, Radix Angelicae Sinensis, Paeonia Lactiflora, Rhizoma Notopterygii, Radix Linderae, Glycyrrhizae, Radix Angelicae Pubescentis, and Radix Et Rhizoma Rhei. The second type of medicinal materials is one, two or three selected from the group cosisting of Zingiber Officinale, Olibanum and Myrrha. The preparation method for the Chinese herbal medicine composition comprises the following steps: adding the first type of medicinal materials and the second type of medicinal materials into a container with organic solvent, heating, filtering, and then condensing the filtrate into an extratum.

Подробнее

Номер записи: 21

26-07-2012 дата публикации

Schisandrae fructus extracts for inhibition or prevention of h1n1 influenza virus infection and its application thereof

Номер: US20120189719A1

Автор: An-rong Lee, Ann Chen, Chen-Wen Yao, Chi-Hong Chu, Chiao-Ying Chien, Chien-Yi Pai, Kuo-Yuan Hwa, Wen-Hsin Huang, Wen-Liang Chang

Принадлежит: NATIONAL DEFENSE MEDICAL CENTER

Disclosed are an Schisandrae fructus extract for inhibition or prevention of influenza and its application, wherein the Schisandrae fructus extract is obtained by water, methanol, or ethanol extraction process and the extract comprises compounds such as schisandrone, benzoylgomisin P, wulignan A1, epigomisin O, epiwulignan A1, and tigloylgomisin P. The extracts and purified compounds of Schisandrae fructus has anti-influenza virus H1N1 and H1N1-TR (a Tamiflu drug resistant virus strain) activities, therefore the extracts and the purified compounds of Schisandrae fructus can be applied as an inhitibory agent of a pharmaceutical composition for treatment or prevention agent for influenza infection.

Подробнее

Номер записи: 22

26-07-2012 дата публикации

Methods and compositions for heavy metal detoxification

Номер: US20120189721A1

Автор: Amy Hall, Anu Desai, Jeffrey S. Bland, Matthew L. Tripp, Veera Konda

Принадлежит: Metaproteomics Llc

Compositions and methods for enhancing heavy metal detoxification are described. The compositions and methods described provide enhanced activity of key detoxification systems including that the induction of phase II detoxification enzymes, such as glutathione S-transferases (GSTs), and NADPH quinone reductase (NQO1) activity.

Подробнее

Номер записи: 23

20-09-2012 дата публикации

Modulation Of Osteoclast Differentiation

Номер: US20120238501A1

Автор: Refael Aharon, Zvi Bar-Shavit

Принадлежит: NITZOZOT Ltd

The present invention concerns the use of an aquaprin-9 (AQP-9) modulator for the preparation of a pharmaceutical composition for treating or preventing a pathological condition associates with unbalanced osteoclast differentiation. In accordance with one embodiment, the modulator is an AQP-9 inhibitor. An example of an inhibitor is phloretin which was shown to inhibit osteoclast differentiation following induction of bone marrow cells with RANKL. The invention also concerns methods for modulating osteoclast differentiation, methods for treating pathological conditions associated with unbalanced osteoclast differentiation as well as pharmaceutical composition comprising such modulators.

Подробнее

Номер записи: 24

27-09-2012 дата публикации

Method of treatment of philadelphia chromosome positive leukaemia

Номер: US20120244116A1

Автор: Angel Francisco Lopez, Devendra Keshaorao Hiwase, Gino Luigi Vairo, Timothy Peter Hughes

Принадлежит: Csl Ltd

The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib. In some embodiments, the agent binds to a receptor involved in signalling by at least one of IL-3, G-CSF and GM-CSF. In some embodiments, the agent is a mutein selected from the group consisting of IL-3 muteins, G-CSF muteins and GM-CSF muteins. In some embodiments, the mutein is an IL-3 mutein. In some embodiments, the agent is a soluble receptor which is capable of binding to IL-3.

Подробнее

Номер записи: 25

27-09-2012 дата публикации

Extended-release formulation for reducing the frequency of urination and method of use thereof

Номер: US20120244221A1

Автор: David A. Dill

Принадлежит: Wellesley Pharmaceuticals LLC

Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.

Подробнее

Номер записи: 26

01-11-2012 дата публикации

Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases

Номер: US20120276121A1

Автор: Cecilie Martin, Christina Dias Rodrigues, Maria M. Mota, Michael Hannus, Miguel Prudencio

Принадлежит: Cenix Bioscience GMBH, Instituto de Medicina Molecular Joao Lobo Antunes

The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.

Подробнее

Номер записи: 27

06-12-2012 дата публикации

Dosing regimens and methods for treating or preventing acute myeloid leukemia

Номер: US20120309845A1

Автор: John NEUSTADT, Steve PIECZENIK

Принадлежит: NBI Pharmaceuticals Inc

The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating acute myeloid leukemia in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone.

Подробнее

Номер записи: 28

06-12-2012 дата публикации

Dosing regimens and methods for treating or preventing myelodysplastic syndrome

Номер: US20120309846A1

Автор: John NEUSTADT, Steve PIECZENIK

Принадлежит: NBI Pharmaceuitcals Inc

The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating myelodysplastic syndrome in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone.

Подробнее

Номер записи: 29

20-12-2012 дата публикации

Nutritional formula for managing angina pectoris

Номер: US20120321728A1

Автор: Ven Subbiah

Принадлежит: Individual

The present invention is a novel nutritional product composition, formulated to be used as medical foods for managing blood flow related problems. The formula comprises clary sage root extract highly enriched for Tanshinones L-arginine, niacin, vitamin C, Vitamin B6, vitamin B12, folate and soy isoflavones. The composition enhances the increased blood flow to the muscle mass. Tanshinone IIA is an inducer of heme oxygenase 1 and suppressor of the induction of inducible nitric oxide synthase, which could result in desirable effects on two important gaseous signaling molecules, namely carbon monoxide and nitric oxide that have significant anti-inflammatory properties.

Подробнее

Номер записи: 30

03-01-2013 дата публикации

Inhibition of the Survival of Gastric Cancer by Cyclohexenone Compounds from Antrodia Camphorata

Номер: US20130005826A1

Автор: Mao-Tien Kuo, Sheng-Yun Liu, Wu-Che Wen

Принадлежит: Golden Biotechnology Corp

The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of gastric cancer cells and be used as a pharmaceutical composition to inhibit the gastric tumor growth.

Подробнее

Номер записи: 31

03-01-2013 дата публикации

Composition and method to alleviate joint pain

Номер: US20130005828A1

Автор: John A. Minatelli, Lingan Rajendran, Rudi E. Moerck, Swati Sebastian Thomas, W. Stephen Hill

Принадлежит: US Nutraceuticals LLC

Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.

Подробнее

Номер записи: 32

17-01-2013 дата публикации

Multicarotenoid beadlets and related method

Номер: US20130017292A1

Автор: Amitabh Chandra, Dawna Salter VENZON, Janjira INTRA, Kerry A. GRANN, Kevin W. Gellenbeck

Принадлежит: ACCESS BUSINESS GROUP INTERNATIONAL LLC

A controlled release beadlet that sequentially releases carotenoids over time within the gastrointestinal tract of a subject, as well as a method of administering the carotenoids. The beadlet provides a specific ratio of carotenoids which release from the beadlet at preselected times during passage through the gastrointestinal tract. The method includes releasing the carotenoids in preselected ratios at specific time intervals in the gastrointestinal tract to mitigate competition between the carotenoids for their uptake, and/or to potentially maximize the uptake of individual carotenoids within a mixed carotenoid formulation.

Подробнее

Номер записи: 33

07-02-2013 дата публикации

Small-molecule inhibitors of dengue and west nile virus proteases

Номер: US20130035284A1

Автор: Scott Gilbertson, Stanley J. Watowich, Suzanne M. Tomlinson

Принадлежит: University of Texas System

The present invention concerns methods and compositions involving small molecule inhibitors for the treatment or prophylaxis of flavivirus infection, such as dengue virus and West Nile virus.

Подробнее

Номер записи: 34

14-02-2013 дата публикации

Dermatological compositions comprising at least one reinoid compound, an anti-irritant compound and benzoyl peroxide

Номер: US20130039995A1

Автор: Claire Mallard

Принадлежит: Galderma Research and Development SNC

Dermatological compositions contain, formulated into a physiologically acceptable medium, at least one retinoid compound selected from among all-trans retinoic acid, isotretinoin, motretinide, and naphthoic acid compounds of formula (I), and salts and esters thereof: wherein R is a hydrogen atom, a hydroxyl radical, a branched or unbranched alkyl radical having from 1 to 4 carbon atoms, an alkoxy radical having from 1 to 10 carbon atoms or a cycloaliphatic radical which is substituted or unsubstituted, and at least one anti-irritant compound and benzoyl peroxide.

Подробнее

Номер записи: 35

21-02-2013 дата публикации

Compositions and methods for the prevention of cardiovascular disease

Номер: US20130045193A1

Автор: Angel E. Gil, Jesus G. Gil, Michael J. Gonzalez

Принадлежит: Angel E. Gil, Jesus G. Gil, Michael J. Gonzalez

The present invention relates to compositions comprising vitamins, minerals and other nutrients and methods for using these compositions for nutritional supplementation to prevent and/or alleviate a patient from the occurrence or negative effects of cardiovascular disease. Specifically, the invention relates to compositions and methods of administering compositions comprising natural CoQ 10 , natural Omega-3 fatty acids, natural bioflavonoids, natural vitamin E, amino acids and derivatives thereof, minerals, extra virgin olive oil, lecithin, B-complex vitamins, and antioxidants.

Подробнее

Номер записи: 36

28-02-2013 дата публикации

Adhesive slow-release formulations for the local administration of curcumin

Номер: US20130052145A1

Автор: Andreas Obwaller

Принадлежит: Orphanidis Pharma Research GmbH

Through the combined use of solvents with polyacrylic acid, it is possible to produce curcumin formulations that are stable in liquid form, while having both mucoadhesive and slow-release properties and ensure a solubility of the active ingredient of up to 15% (w/v).

Подробнее

Номер записи: 37

21-03-2013 дата публикации

Oral Formulations For Promoting Cellular Purification

Номер: US20130071369A1

Автор: Barger Jamie Louis, BARTLETT Mark, Ferguson Scott B., Mastaloudis Angela, Prolla Tomas Alberto, Weindruch Richard, Wood Steve

Принадлежит: NSE Products, Inc.

An oral formulation includes a plurality of agents that promote cellular detoxification. Agents can be included that modulate expression of Nrf2-associated genes upon ingestion of the oral formulation by a subject, wherein the Nrf2-associated genes include at least one gene encoding intrinsic antioxidants, and at least one gene encoding cellular detoxifiers. In addition, at least one of the plurality of agents attenuates inflammation. 1. An oral formulation comprising a plurality of agents that modulate expression of Nrf2-associated genes upon ingestion of the oral formulation by a subject , wherein the Nrf2-associated genes include at least one gene encoding intrinsic antioxidants , and at least one gene encoding cellular detoxifiers , and wherein at least one of the plurality of agents attenuates inflammation.2. The oral formulation of claim 1 , wherein the Nrf2-associated genes are selected from the group consisting of NFE2L2 claim 1 , GCLM claim 1 , GCLC claim 1 , GSR claim 1 , GSTA1 claim 1 , GPX1 claim 1 , GPX4 claim 1 , HMOX1 claim 1 , NQO1 claim 1 , SRXN1 claim 1 , SQSTM1 claim 1 , SOD1 claim 1 , UGT1A6 claim 1 , NOS2 claim 1 , NOS3 claim 1 , and PTGS2.3. The oral formulation of claim 2 , wherein at least one of the plurality of agents substantially reverses an age-related change in expression of at least one of the Nrf2-associated genes.4. The oral formulation of claim 1 , wherein the plurality of agents combine to modulate expression of at least five Nrf2-associated genes.5. The oral formulation of claim 1 , wherein at least one of the plurality of agents upregulates a gene encoding intrinsic antioxidants.6. The oral formulation of claim 1 , wherein at least one of the plurality of agents upregulates a gene encoding cellular detoxifiers.7. The oral formulation of claim 1 , wherein at least one of the plurality of agents stimulates autophagy in a tissue of the subject.8. The oral formulation of claim 1 , wherein the plurality of agents include at least two ...

Подробнее

Номер записи: 38

21-03-2013 дата публикации

DRUGS, DERIVATIVES AND ANALOGS CONTAINING ADAMANTANE STRUCTURES OF NEW INDICATION APPLICATIONS OF ANTI-TUMOR

Номер: US20130072553A1

Автор: XU LIFENG

Принадлежит:

This invention relates to the drugs, derivatives and analogs containing adamantane structures of new indication applications of anti-tumor. The invention also relates to above compounds to treat tumors and other diseases with FIG. . These drugs, derivatives and analogs are generated by the modification of the parent or fragment structures and formation of pharmaceutically acceptable salts, complex salts or prodrug. The drugs, derivatives and analogs as described are administered alone or together with at least one known anti-tumor and immune chemotherapeutic agent including treatment of viral, bacterial and fungal diseases, neurological diseases, endocrine system diseases, and immune system diseases. 2. The drugs claim 1 , derivatives and analogs according to claim 1 , wherein:compound 1, compound 2, compound 3, compound 4, compound 5 and compound 6, derivatives and analogs are generated by the modification of the parent or fragment structures.3. The drugs claim 2 , derivatives and analogs according to claim 2 , wherein: the derivatives and analogs prepared by direct synthesis or structural modification of the drugs as described compound 1 claim 2 , compound 2 claim 2 , compound 3 claim 2 , compound 4 claim 2 , compound 5 and compound 6 are relevance to the drugs as described compound 1 claim 2 , compound 2 claim 2 , compound 3 claim 2 , compound 4 claim 2 , compound 5 and compound 6 in chemical structures and pharmaceutical activities.4. The drugs claim 3 , derivatives and analogs according to claim 3 , wherein:The drugs, derivatives and analogs are selected from the exemplified examples or pharmaceutically acceptable salts formed by organic acid, inorganic acid, organic base, inorganic base, prodrug or complex salts.5. The drugs claim 3 , derivatives and analogs according to claim 3 , claim 3 , and wherein:This invention relates to the drugs, derivatives and analogs containing adamantane structures of new indication applications of anti-tumor including: the ...

Подробнее

Номер записи: 39

11-04-2013 дата публикации

INHIBITORS OF INFLUENZA ENDONUCLEASE ACTIVITY AND TOOLS FOR THEIR DISCOVERY

Номер: US20130090300A1

Автор: Arnold Eddy, Bauman Joseph D., Das Kalyan, PATEL Disha

Принадлежит:

The invention provides inhibitors of influenza endonuclease activity and tools for their discovery. 1. An isolated or purified amino acid sequence at least 95% identical to SEQ ID NO: 1 or 2.2. The amino acid of claim 1 , which is at least 95% identical to SEQ ID NO:1.3. The amino acid of claim 1 , which is at least 95% identical to SEQ ID NO:2.4. The amino acid of claim 1 , wherein the sequence is SEQ ID NO:1.5. The amino acid of claim 1 , wherein the sequence is SEQ ID NO:2.6. The amino acid of claim 1 , wherein the sequence is about 200 to about 220 amino acids in length.7. The amino acid sequence of claim 6 , wherein the sequence is about 209 amino acids in length.8. An isolated or purified amino acid sequence that comprises an amino acid sequence at least 95% identical to SEQ ID NO:2 that further comprises an N-terminal or C-terminal tandem His-tag.9. An isolated or purified nucleic acid sequence encoding the amino acid sequence of .10. An expression construct comprising the nucleic acid of .11. An expression vector comprising the construct of .12. A crystal formed from the amino acid of .13. A crystal of an endonuclease characterized by the parameters described in Table 1 or 2 claim 1 , wherein the parameters described in Table 1 or 2 can vary by +/−5%.14. The crystal of claim 13 , which is Form I claim 13 , Form II or Form III as defined in Table 1 or 2 claim 13 , wherein the parameters described in Table 1 or 2 can vary by +/−5%.15. The crystal of claim 14 , which is Form I.16. The crystal of claim 14 , which is Form II.17. The crystal of claim 14 , which is Form III.18. A method to determine whether a compound inhibits endonuclease activity claim 13 , comprising contacting the compound with the crystal of and determining whether the compound binds the endonuclease at or near the active site in a manner that would inhibit the enzyme.19. A method to determine whether a compound inhibits endonuclease activity claim 1 , comprising contacting the compound with ...

Подробнее

Номер записи: 40

11-04-2013 дата публикации

CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS

Номер: US20130090355A1

Автор: Bresnick Anne R.

Принадлежит: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY

The present invention provides methods of preventing or inhibiting tumor metastasis in a subject by administering a therapeutically effective amount of (1) a compound from a group of enumerated compounds, or a pharmaceutically acceptable salt thereof; (2) an agent that covalently modifies at least one cysteine residue of S100A4 protein; or (3) an agent that inhibits the interaction between S100A4 and myosin-IIA. 2. The method of claim 1 , wherein the compound is the compound of formula (I).5. The method of claim 1 , wherein the compound is the compound of formula (III).8. The method of claim 1 , wherein the compound comprises 2 claim 1 ,3-dihydrobenzo[g][1 claim 1 ,4]benzodithiine-5 claim 1 ,10-dione claim 1 , 2 claim 1 ,3-bis(2-hydroxyethylsulfanyl)naphthalene-1 claim 1 ,4-dione claim 1 , 2-(2-hydroxyethylsulfanyl)naphthalene-1 claim 1 ,4-dione claim 1 , 3-(1 claim 1 ,4-dioxonaphthalen-2-yl)sulfanylpropanoic acid claim 1 , 2-ethylsulfanylnaphthalene-1 claim 1 ,4-dione claim 1 , 4 claim 1 ,11-diaminonaphtho[2 claim 1 ,3-f]isoindole-1 claim 1 ,3 claim 1 ,5 claim 1 ,10-tetrone claim 1 , 2-(3-methyl-1 claim 1 ,4-dioxonaphthalen-2-yl)sulfanylacetic acid claim 1 , 2-butylsulfanylnaphthalene-1 claim 1 ,4-dione claim 1 , 2-ethylsulfanyl-3-methylnaphthalene-1 claim 1 ,4-dione claim 1 , 2-(2-hydroxyethylsulfanyl)-3-methylnaphthalene-1 claim 1 ,4-dione claim 1 , 2-methyl-3-methylsulfanylnaphthalene-1 claim 1 ,4-dione claim 1 , (1 claim 1 ,4-dioxonaphthalen-2-yl) 4-methylbenzoate claim 1 , N-[3-(4-chlorophenyl)sulfanyl-1 claim 1 ,4-dioxonaphthalen-2-yl]acetamide claim 1 , 2-benzylsulfanyl-3-methylnaphthalene-1 claim 1 ,4-dione claim 1 , N-(3-chloro-1 claim 1 ,4-dioxonaphthalen-2-yl)-N-(4-fluorophenyl)acetamide claim 1 , 2-methylquinoline-5 claim 1 ,8-dione claim 1 , N-(7-chloro-5 claim 1 ,8-dioxoquinolin-6-yl)acetamide claim 1 , 6-amino-7-chloroquinoline-5 claim 1 ,8-dione claim 1 , 7-amino-6-methoxyquinoline-5 claim 1 ,8-dione claim 1 , 6 claim 1 ,7-dichloroquinoline-5 claim ...

Подробнее

Номер записи: 41

18-04-2013 дата публикации

ANTIOXIDANT COMPOSITION

Номер: US20130095049A1

Автор: Alonso Varona Ana Isabel, Azcoitia Ramsden Iker, Castro Feo Maria Begoña, Del Olmo Basterrechea Maite, Herrero De Miguel Jone, Palomares Casado Teodoro

Принадлежит: HISTOCELL, S.L.

The present invention relates to an antioxidant composition comprising a combination of galatomannan and N-acetyl cysteine for its use in the treatment of a skin disease or condition resulting from reactive oxygen species production in the skin or involving reactive oxygen species production in the skin, to a hydrogel containing said combination as well as to dressing wounds comprising said hydrogel and its use in the healing of ulcers, wounds, burns and scalds. 122-. (canceled)23. A method for therapeutic or prophylactic treatment of a skin disease or condition resulting from reactive oxygen species production in the skin of a subject or of a skin disease or condition which involves reactive oxygen species production in the skin of a subject , the method comprising topical administration of a therapeutically effective amount of a composition comprising galactomannan and N-acetyl cysteine.24. The method according to claim 23 , wherein the galactomannan comprises locust bean gum.25. The method according to claim 23 , wherein the reactive oxygen species production results from exposure of the subject to sunlight radiation claim 23 , chemical agents claim 23 , radiotherapy or chemotherapy.26. The method according to claim 23 , wherein the skin disease or condition resulting from reactive oxygen species production in the skin of a subject is selected from the group consisting of sunburn claim 23 , photosensitivity claim 23 , immunosuppression claim 23 , premature aging claim 23 , psoriasis claim 23 , an immunological disease claim 23 , a localized or widespread inflammation claim 23 , a bacterial or fungal infection claim 23 , skin rashes claim 23 , systemic oxidative stresses claim 23 , actinic keratosis claim 23 , and skin cancer selected from the group consisting of basal cell cancer claim 23 , squamous cell cancer claim 23 , and malignant melanoma.27. The method according to claim 23 , wherein skin disease or condition which involves the reactive oxygen species ...

Подробнее

Номер записи: 42

18-04-2013 дата публикации

Method for producing hematopoietic stem cells

Номер: US20130095085A1

Автор: Atsushi Iwama, Taito Nishino

Принадлежит: Chiba University NUC, Nissan Chemical Corp

An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R 1 to R 6 are as defined in the description).

Подробнее

Номер записи: 43

18-04-2013 дата публикации

PALATINOSE FOR ENHANCING DIETARY SUPPLEMENT AND PHARMACEUTICAL DELIVERY

Номер: US20130095125A1

Автор: Kneller Bruce W.

Принадлежит:

The present invention is directed to a dietary supplement comprising palatinose or a derivative thereof. The dietary supplement may be a nutritional product, a sports performance product, a weight loss product or a meal replacement product. The present invention is also directed to a method of increasing the absorption of a compound into the bloodstream, cells and tissue comprising administering palatinose, or a derivative thereof, in combination with the compound. 1. A dietary supplement comprising palatinose and one or more compounds selected from the group consisting of:(a) a composition consisting of one amino acid or a salt, ester or chelate thereof; and(b) a composition consisting of two amino acids or a salt, ester or chelate of said amino acids.2. The dietary supplement of wherein the composition consisting of two amino acids or a salt claim 1 , ester or chelate of said amino acids is a dipeptide.3. The dietary supplement of wherein the dipeptide is carnitine or a salt claim 2 , ester or chelate thereof.4. The dietary supplement of wherein the dietary supplement further comprises one or more compounds selected from the group consisting of a sugar; a stimulant; creatine or a salt claim 1 , ester or chelate thereof; coenzyme Q-10; a mineral; an undigestible bulk-forming starch; and carbon dioxide.5. The dietary supplement of wherein the dietary supplement further comprises carbon dioxide claim 1 , and one or more compounds selected from the group consisting of trehalose; amylose; glucose; a methylxanthine; creatine or a salt claim 1 , ester or chelate thereof; amylopectin; calcium carbonate; sodium bicarbonate; glucuronolactone; sulbutiamine or fursultiamine; orotic acid; vinpocetine or rhodiola rosea; coenzyme Q-10; and cellulose.6. The dietary supplement of wherein the concentration of palatinose is between about 1% and about 85%.7. The dietary supplement of wherein the concentration of palatinose is between about 10% and about 50%.8. The dietary supplement ...

Подробнее

Номер записи: 44

18-04-2013 дата публикации

Topical vitamin d and ubiquinol oral supplement compositions

Номер: US20130095155A1

Автор: Dale G. Brown, William A. Mchale

Принадлежит: Premier Dental Products Co

A topical vitamin D and UBIQUINOL supplement composition useful in treating oral inflammation and reducing oxidative stress comprising: a supplement mixture of vitamin D and UBIQUINOL in an aqueous-free emulsion containing: spilanthes extract, stabilizing compositions for UBIQUINOL and trans-oral mucosal absorption facilitators for the supplement mixture; where the emulsion forms a mucoadhesive gel in the presence of saliva, that effects passive diffusion through the oral mucosa of the supplement mixture and spilanthes extract regulating: in vivo availability and immune response of the supplement mixture, and maintaining adequate levels of circulating vitamin D and of adjunctively administered UBIQUINOL, while minimizing the risk of hypercalcemia.

Подробнее

Номер записи: 45

25-04-2013 дата публикации

HAIR GROWTH STIMULANT

Номер: US20130101569A1

Автор: Weston Anthony R.

Принадлежит:

A composition of a mixture of vitamin and herbal supplements. Supplementation of the composition promotes hair growth and thickness by increasing the number of hairs and preventing hair loss. The concentration of the vitamin and herbal supplements in the composition is suitably about 0.01-100%. The composition may comprise a suitable carrier, solvent and/or emulgent. The composition may be, for example, an internally ingested tablet, a capsule, drops or a suspension. This formulation will enhance the hair thickness and provide elements for growing hair in humans and animals. 1. Promoting hair growth and preventing hair loss thereof administering a composition of mixed vitamin and herbal supplements wherein said concentration of a mixed vitamin and herbal supplements is about 0.1%.2. The composition of claim 1 , wherein said composition of vitamin and herbal supplements are a mixture of Biotin claim 1 , Calcium claim 1 , Chromium claim 1 , Copper claim 1 , DHA-docosahexaenoic acid claim 1 , EPA-eicosapentaenoic acid claim 1 , Fish oil claim 1 , Folic acid claim 1 , Ginkgo biloba claim 1 , Ginseng claim 1 , Iodine claim 1 , Iron claim 1 , Magnesium claim 1 , Manganese claim 1 , Molybdenum claim 1 , Niacin claim 1 , Omega-3 claim 1 , Pantothenic acid claim 1 , Riboflavin claim 1 , Saw palmetto claim 1 , Selenium claim 1 , Thiamin claim 1 , Vitamin A claim 1 , Vitamin B12 claim 1 , Vitamin B6 claim 1 , Vitamin C claim 1 , Vitamin D-cholecalciferol claim 1 , Vitamin E claim 1 , Vitamin K claim 1 , and Zinc.3. The composition of claim 2 , wherein said composition comprises a suitable carrier claim 2 , solvent and/or emulgent.4. The composition of claim 2 , wherein said composition is administered in the form of an oral dosage.5. The composition of claim 2 , wherein said oral dosage is in the form of an internally ingested tablet claim 2 , a capsule claim 2 , drops or a suspension.6. The composition of claim 1 , wherein said oral dosage promotes healthy micronutrient ...

Подробнее

Номер записи: 46

02-05-2013 дата публикации

DIETARY FORMULATIONS

Номер: US20130108706A1

Автор: Svennevig Katja

Принадлежит:

The present invention relates to the field of nutritional support for individuals and reducing the effects of muscle conditions caused by high levels of physical activity. In particular, the invention provides dietary formulations, compositions comprising these formulations and uses of these compositions to support the body's muscle regeneration process. 124.-. (canceled)25. A dietary formulation , comprising:a. an oil obtained from a marine invertebrate;b. one or more carotenoids; andc. Vitamin C and/or Vitamin E.26. The formulation of claim 25 , wherein the formulation comprises Vitamin C and Vitamin E.27. The formulation of claim 25 , wherein the one or more carotenoids comprise lutein claim 25 , zeaxanthin claim 25 , and astaxanthin.28. The formulation of claim 25 , wherein the formulation comprises:a. an oil obtained from a marine invertebrate;b. lutein, zeaxanthin, and astaxanthin; andc. Vitamin C and Vitamin E.29. The formulation of claim 25 , wherein the oil is obtained from Crustacea or Mollusca.30. The formulation of claim 29 , wherein the oil is obtained from krill or calamari.31. The formulation of claim 25 , wherein the oil obtained from a marine invertebrate is at a concentration of 30% to 90% (w/w) claim 25 , and wherein the one or more carotenoids are at a combined concentration of 0.1 to 10% (w/w).32. The formulation of claim 31 , wherein the oil obtained from a marine invertebrate is at a concentration of 40% to 60% (w/w).33. The formulation of claim 31 , wherein the one or more carotenoids are at a combined concentration of 0.18 to 4.5% (w/w).34. The formulation of claim 30 , wherein the formulation comprises:a. 225 to 350 mg krill oil or calamari oil;b. 5 to 7.5 mg lutein, 1 to 1.5 mg zeaxanthin, and 1 to 5 mg astaxanthin; andc. 10 to 150 mg Vitamin C and 5 to 30 mg Vitamin E.35. The formulation of claim 30 , wherein the formulation comprises:a. 40 to 60 w/w % krill oil or 35% to 50% calamari oil;b. 0.75 to 1.35 w/w % lutein, 0.15 to 0.28 w/w % ...

Подробнее

Номер записи: 47

02-05-2013 дата публикации

Formulations of quinones for the treatment of ophthalmic diseases

Номер: US20130109759A1

Автор: Guy M. Miller

Принадлежит: Edison Phamaceuticals Inc

A formulation comprising an ophthalmically effective amount of one or more quinones of Formula I. Use of a formulation comprising one or more quinones of Formula I for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are associated with a neurodegenerative or trauma disorder is also discussed. A method of treating or controlling the ocular symptoms associated with neurodegenerative diseases or trauma with a formulation comprising one or more quinones of Formula I is also discussed. A method of treating or controlling the ocular symptoms associated with mitochondrial myopathies with a formulation comprising one or more quinones of Formula I is also discussed.

Подробнее

Номер записи: 48

09-05-2013 дата публикации

Anti-Aging Formulations

Номер: US20130115195A1

Автор: Cappello John V.

Принадлежит:

A dietary supplement based on fucoidan, blue-green algae, phycocyanin and phenylethylamine is fortified with one or more of curcumin, silymarin, resveratrol, astragalus root extract, astragoloside IV, vitamin D3, vitamin C, anhydrous trimethylglycine and brewers yeast to stimulate stem cell production and reduce the rate of telomere reduction or shortening. This can result in the repair of existing body cells and enhance longevity by stimulating the production of new stem cells and maintaining the telomeres on new stem cells as well as existing cells. The dietary supplement supports an increased life span by enhancing metabolic function, activating SIRT-1 anti-aging genes, and encouraging the production of new cells with longer telomeres. 1. A dietary composition for stimulating stem cell production and reducing inflammation , comprising:fucoidan in the amount sufficient for promoting an increase in the circulation of stem cells; andphycocyanin in an amount sufficient for reducing inflammation.2. The composition of claim 1 , wherein said phycocyanin is provided in the form of Arthrospira platensis and wherein claim 1 , said fucoidan comprises from about 10% to about 90% by weight of the combined weight of said fucoidan and said phycocyanin and said phycocyanin comprises from about 10% to about 90% by weight of the combined weight of said fucoidan and said phycocyanin.3. The dietary composition of claim 1 , further comprising blue-green algae.4. The dietary composition of claim 3 , wherein said blue-green algae comprises Apanizominom flos aqua (AFA).5. The dietary composition of claim 1 , further comprising at least one of the group consisting of blue green algae claim 1 , phenylethylamine claim 1 , curcumin claim 1 , silymarin claim 1 , resveratrol claim 1 , astragalus root extract claim 1 , astragoloside IV claim 1 , L-carnosine claim 1 , vitamin D3 claim 1 , vitamin C and anhydrous trimethylglycine.6. The dietary composition of claim 1 , further comprising ...

Подробнее

Номер записи: 49

09-05-2013 дата публикации

ANTI-INFLAMMATORY COMPOSITIONS FOR TREATING NEURO-INFLAMMATION

Номер: US20130115202A1

Автор: Theoharides Theoharis C.

Принадлежит: THETA BIOMEDICAL CONSULTING & DEVELOPMENT CO., INC

This disclosure pertains to methods of treating a neuro-inflammation disorder in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising a flavonoid, or a structurally related analogue, olive kernel extract, hydroxytyrosol, and berberine, and, optionally, one or more ingredients selected from the group consisting of a sulfated proteoglycan, oleocanthal, a CRH antagonist, S adenosylmethionine, a histamine 1 receptor antagonist, a histamine 3 receptor agonist, emu oil, oregano oil, grape seed oil, aloe extract, biotin, and selenium. Certain of the present compositions are useful in protecting against or treating neuro-inflammation associated with allergies, Alzheimer's disease (AD), atherosclerosis, asthma, Autistic Spectrum Disorders (ASD). 1. A method of treating a neuro-inflammation disorder in a subject , comprising administering to a subject in need thereof an effective amount of a composition comprising a flavonoid , or a structurally related analogue , olive kernel extract , hydroxytyrosol , and berberine , and , optionally , one or more ingredients selected from the group consisting of a sulfated proteoglycan , oleocanthal , a CRH antagonist , S-adenosylmethionine , a histamine-1 receptor antagonist , a histamine-3 receptor agonist , emu oil , oregano oil , grape seed oil , aloe extract , biotin , huperzine A , and selenium.2. The method of claim 1 , wherein the composition further comprises a biologic immune modulator.3. The method of claim 2 , wherein the biologic immune modulator is a T cell inhibitor.4. The method of claim 2 , wherein the biologic immune modulator is a TNF inhibitor.5. The method of claim 2 , wherein the biologic immune modulator is an mTOR inhibitor.6. The method of claim 1 , wherein the flavonoid is selected from the group consisting of luteolin claim 1 , tetramethoxyluteolin claim 1 , quercetin claim 1 , myricetin claim 1 , genistein claim 1 , kaempferol claim 1 , (−) ...

Подробнее

Номер записи: 50

09-05-2013 дата публикации

METHOD FOR IDENTIFYING THERAPEUTIC AGENTS FOR TREATMENT OF CANCER

Номер: US20130116335A1

Автор: Langhans Sigrid Anne-Barbara, Lee Seung Joon

Принадлежит: The Nemours Foundation

The presence of phosphorylated Cdc27 in cancer cells is utilized to identify patients likely to benefit from treatment with a chemotherapeutic agent that binds to, or binds to and crosslinks, phosphorylated Cdc27, e.g., curcumin, or to determine whether patients undergoing such treatment will continue to respond effectively. Candidate compounds are screened for anticancer effect by testing the ability to bind to or crosslink phosphorylated Cdc27. 1. A method of identifying a patient with cancer who is most likely to benefit from treatment with an agent that binds phosphorylated Cdc27 , the method comprising:(a) obtaining a sample of cancer cells from the patient;(b) determining whether the sample comprises cancer cells that contain phosphorylated Cdc27; and(c) identifying the patient as one most likely to benefit from treatment with an agent that binds phosphorylated Cdc27, if the cancer cells comprise phosphorylated Cdc27.2. The method according to claim 1 , wherein the agent that binds phosphorylated Cdc27 crosslinks said phosphorylated Cdc27 claim 1 , and the method is for identifying the patient as one most likely to benefit from treatment with an agent that crosslinks phosphorylated Cdc27 claim 1 , if the cancer cells comprise phosphorylated Cdc27.3. A method of predicting whether a cancer patient is afflicted with a tumor that will respond effectively to treatment with an agent that binds phosphorylated Cdc27 claim 1 , the method comprising:(a) obtaining a sample of the patient's tumor;(b) determining whether the sample comprises tumor cells that contain phosphorylated Cdc27; and(c) predicting that the tumor will respond effectively to treatment with an agent that binds phosphorylated Cdc27, if tumor cells of the sample contain phosphorylated Cdc27.4. The method according to claim 3 , wherein the agent that binds phosphorylated Cdc27 crosslinks said phosphorylated Cdc27 claim 3 , and the method is for predicting that the tumor will respond effectively to ...

Подробнее

Номер записи: 51

09-05-2013 дата публикации

Treatment of ataxia telangiectasia

Номер: US20130116336A1

Автор: William D. Shrader

Принадлежит: Individual

The present invention relates to methods of treating Ataxia-Telangiectasia (A-T) or Ataxia-telangiectasia like disorder (ATLD) with compounds such as tocotrienol quinones and tocotrienol hydroquinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.

Подробнее

Номер записи: 52

16-05-2013 дата публикации

METHODS OF REDUCING 15-F2T-ISOP LEVELS IN MAMMALS

Номер: US20130123368A1

Автор: Kuhrts Eric

Принадлежит: BIOACTIVES, INC.

Methods of reducing 15-F-IsoP levels in mammalian subjects are disclosed herein. In addition, methods of reducing or preventing oxidative stress and treating or preventing related diseases are disclosed. 1. A method of reducing levels of 15-F-Isoprostane (15-F-IsoP) in a mammalian subject , said method comprising administering to said mammalian subject an amount of xanthohumol sufficient to reduce levels of 15-F-IsoP in said mammalian subject.2. The method of claim 1 , wherein levels of 15-F-IsoP are reduced in the urine of said mammalian subject.3. The method of claim 2 , wherein said amount of xanthohumol is sufficient to reduce levels of 15-F-IsoP by at least 10%.4. The method of claim 2 , wherein said amount of xanthohumol is sufficient to reduce levels of 15-F-IsoP by at least 20%.5. The method of claim 2 , wherein said amount of xanthohumol is sufficient to reduce levels of 15-F-IsoP by at least 30%.6. The method of claim 2 , wherein said amount of xanthohumol is sufficient to reduce levels of 15-F-IsoP by at least 40%.7. The method of claim 1 , wherein said xanthohumol is administered as a water-soluble formulation.8. The method of claim 7 , wherein said xanthohumol water-soluble formulation comprises: a) xanthohumol; and b) a non-ionic surfactant.9. The method of claim 8 , wherein said non-ionic surfactant is a non-ionic water soluble mono- claim 8 , di- claim 8 , or tri-glyceride; non-ionic water soluble mono- or di-fatty acid ester of polyethyelene glycol; non-ionic water soluble sorbitan fatty acid ester; polyglycolyzed glyceride; non-ionic water soluble triblock copolymers; or derivative thereof.10. The method of claim 8 , wherein said non-ionic surfactant is macrogolglycerol hydroxystearate.11. The method of claim 1 , wherein said amount of xanthohumol is at least 1 mg.12. The method of claim 1 , wherein said amount of xanthohumol is at least 3 mg.13. The method of claim 1 , wherein said amount of xanthohumol is at least 5 mg.14. The method of claim 1 , ...

Подробнее

Номер записи: 53

23-05-2013 дата публикации

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER BY TARGETING AND INHIBITING CANCER STEM CELLS

Номер: US20130129809A1

Автор: Shankar Sharmila, Srivastava Rakesh K.

Принадлежит: Glax L.L.C.

The invention relates to compositions and methods for treating cancer comprising administering to a subject in need a pharmaceutically effective dose of a cancer stem cell inhibitor, methods of inhibiting the growth of cancer stem cells or tumor initiating cell comprising administering to a subject in need a pharmaceutically effective dose of a cancer stem cell inhibitor, and methods of enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells comprising administering to a subject in need a pharmaceutically effective dose of a chemotherapeutic drug and a pharmaceutically effective dose of a cancer stem cell inhibitor. 1. A method of treating or preventing cancer by targeting and inhibiting cancer stem cells , comprising administering to a subject in need thereof a pharmaceutically effective dose of a cancer stem cell inhibitor.2. The method of claim 1 , wherein the cancer stem cell inhibitor is selected from one or more of rottlerin claim 1 , embelin claim 1 , ellagic acid claim 1 , sulforaphane claim 1 , resveratrol claim 1 , honokiol claim 1 , curcumin claim 1 , diallyltrisulfide claim 1 , quercetin claim 1 , epigallocatechin gallate (EGCG) claim 1 , SAHA claim 1 , m-Carboxycinnamic acid bis-hydroxamine claim 1 , MS-275 claim 1 , SAHA/vornostat claim 1 , m-Carboycinnamic acid bis-hydroxamine claim 1 , benzyl selenocyanate (BSC) claim 1 , benzyl isothiocyanate (BITC) claim 1 , phenyl isothiocyanate (PITC) claim 1 , anthothecol claim 1 , sanguinarine claim 1 , mangostine claim 1 , and 5-aza-2′-deoxycytidine claim 1 , or a pharmaceutically acceptable salt or ester thereof.3. The method of claim 2 , wherein the cancer stem cell inhibitor is rottlerin claim 2 , or a pharmaceutically acceptable salt or ester thereof.4. The method of claim 2 , wherein the cancer stem cell inhibitor is embelin claim 2 , or a pharmaceutically acceptable salt or ester thereof.5. The method of claim 2 , wherein the cancer stem cell inhibitor is sulforaphane ...

Подробнее

Номер записи: 54

23-05-2013 дата публикации

METHODS AND COMPOSITIONS FOR IMPROVING THE HEALTH OF ANIMALS

Номер: US20130131183A1

Автор: DAROSZEWSKI Janusz, Dick Clayton Paul, Verzberger-Epshtein Isabella

Принадлежит: Chemaphor Inc.

The invention features compositions and methods for the administration of an oxidatively transformed carotenoid, or a fractionated component thereof, for improving the health of animals, such as increasing joint mobility, increasing activity, and improving coat quality. 1. A method of increasing joint mobility of an animal in need thereof or increasing the activity level in an animal , said method comprising administering to said animal a composition comprising oxidatively transformed carotenoid , or a fractionated component thereof , in an amount sufficient to increase said joint mobility or increase said activity level.2. (canceled)3. A method of improving or maintaining the coat quality of an animal , said method comprising administering to said animal a composition comprising oxidatively transformed carotenoid , or a fractionated component thereof , in an amount sufficient to improve or maintain said coat quality.4. (canceled)5. A method of reducing discoloration in an eye of an animal , said method comprising administering to said animal a composition comprising oxidatively transformed carotenoid , or a fractionated component thereof , in an amount sufficient to reduce said discoloration.6. The method of claim 1 , wherein said composition is administered daily.7. The method of claim 6 , wherein from 0.1 mg/kg body weight to 3 mg/kg body weight of oxidatively transformed carotenoid claim 6 , or a fractionated component thereof claim 6 , is administered to said animal daily.8. The method of claim 1 , wherein said composition is mixed with food and administered orally to said animal.9. The method of claim 8 , wherein said food is a wet animal food or a dry animal food or said food is in the form of a kibble claim 8 , a chew claim 8 , a tablet claim 8 , or a soft edible treat.10. (canceled)11. The method of claim 1 , wherein said composition is administered to said animal as an oral supplement.12. The method of claim 11 , wherein said oral supplement is a palatable ...

Подробнее

Номер записи: 55

30-05-2013 дата публикации

PIG FEED, AND METHOD FOR FEEDING SAME

Номер: US20130136724A1

Автор: Hosoe Kazunori, OHARA Takaaki, TANI Shinichi, Uemura Tomohito

Принадлежит: KANEKA CORPORATION

An object of the present invention is to provide a method for improving a farrowing rate of sows or improving growth and productivity of postnatal piglets, and a feed used in the method. The present invention relates to a method for improving a farrowing rate of a sow or improving growth and productivity of postnatal piglets, the method comprising administering coenzyme Q to a swine. 1. A method for improving a farrowing rate of a sow or improving growth and productivity of postnatal piglets , characterized in that the method comprises administering coenzyme Q to a swine.2. The method according to claim 1 ,wherein the coenzyme Q is administered to a mother sow.3. The method according to claim 2 ,wherein the coenzyme Q is administered to a mother sow during pregnancy.4. The method according to claim 2 ,wherein the coenzyme Q is administered to a mother sow during pregnancy at least for one month after mating.5. The method according to claim 2 ,wherein the coenzyme Q is administered to a mother sow at least for one month prior to parturition.6. The method according to claim 2 ,wherein the coenzyme Q is administered to a mother sow during lactation.7. The method according to claim 2 , wherein the method further comprises administering the coenzyme Q to a postnatal piglet.8. The method according to claim 1 ,wherein the improvement in a farrowing rate of a sow is observed as an increase in fertility, a shortening of the interval of recurrent estrous, or an increase in the number of total births or in the number of piglets survived.9. The method according to claim 1 ,wherein the improvement in growth and productivity of postnatal piglets is observed as an increase in the number of weaned piglets, an increase in weight gain, or an increase in the weight at weaning.10. The method according to claim 1 ,wherein a feed containing the coenzyme Q is administered to a mother sow.11. The method according to claim 1 ,wherein the coenzyme Q is derived from yeast.12. A feed for a ...

Подробнее

Номер записи: 56

30-05-2013 дата публикации

Skin Collagen Enhancing Agent

Номер: US20130137640A1

Автор: KAMO Shuichi, KAWAHARA Rumi, SATO Toshiro

Принадлежит: J-OIL MILLS, INC.

A composition includes a food ingredient or nutrient with safety and experience having been eaten for a long time and that shows a collagen enhancing activity. The food ingredient or nutrient of the composition includes a skin collagen enhancing agent that includes menaquinone-7 as an active ingredient. The composition including skin collagen enhancing agent can be administered percutaneously or orally as a drug, a cosmetic, or a supplement. 1. A composition comprising a skin collagen enhancing agent , the skin collagen enhancing agent comprising menaquinone-7 as an active ingredient.2. A percutaneously administrative agent comprising the composition of .3. The percutaneously administrative agent of claim 2 , wherein the composition is in the form of a solution claim 2 , an emulsion or a cream.4. An orally administrative agent comprising the composition of .5. The orally administrative agent of claim 4 , wherein the composition is in the form of at least one of a powder claim 4 , granules claim 4 , a capsule claim 4 , a pill claim 4 , a tablet claim 4 , a liquid preparation claim 4 , a suspension claim 4 , an emulsion claim 4 , and a syrup.6. The composition of claim 1 , wherein the composition comprises a drug claim 1 , the drug further comprising at least one additive comprising at least one of an excipient claim 1 , a disintegrator claim 1 , a binder claim 1 , a lubricant claim 1 , a vitamin claim 1 , a xanthine derivative claim 1 , a pH adjuster claim 1 , a cooling agent claim 1 , a suspending agent claim 1 , a thickener claim 1 , a solubilizing agent claim 1 , an antioxidant claim 1 , a coating agent claim 1 , a plasticizer claim 1 , a surfactant claim 1 , water claim 1 , an alcohol claim 1 , a water-soluble polymer claim 1 , a sweetener claim 1 , a flavoring substance claim 1 , an acidifier claim 1 , a flavoring agent claim 1 , and a coloring agent.7. The composition of claim 1 , wherein the composition comprises a cosmetic claim 1 , the cosmetic further ...

Подробнее

Номер записи: 57

30-05-2013 дата публикации

USE OF CANTHAXANTHIN AND/OR 25-OH D3 FOR IMPROVED REPRODUCTIVITY AND PERFORMANCE OF ROOSTERS

Номер: US20130137662A1

Автор: Hernandez Jose Maria

Принадлежит:

The present invention relates to the use canthaxanthin and/or 25-hydroxy vitamin D3 (25-OH D3) for improving reproductive performance of roosters. More particularly, the invention relates to the use of Canthaxanthin and/or 25-hydroxy canthaxanthin in the manufacture of a food or veterinary composition for improving reproductive performance of roosters. 1. The use of canthaxanthin and/or at least one vitamin D metabolite for improving reproductive performance of roosters.2. The use according to claim 1 , wherein the vitamin D metabolite is 25-hydroxy vitamin D3.3. The use of canthaxanthin and or 25-hydroxy vitamin D3 in the manufacture of a food or veterinary composition for improving reproductive performance of roosters.4. The use as in in the manufacture of a poultry food comprising from about 10 μg/kg to about 100 μg/kg of 25-hydroxy vitamin D3 and from about 2 to 100 ppm canthaxanthin claim 1 , preferably from about 2 ppm to 10 ppm.5. A method for improving reproductive performance of roosters claim 1 , which comprises administering to an animal in need of such treatment an amount of about 2 ppm to 100 ppm claim 1 , preferably 2 to 10 ppm of canthaxanthin and/or about 10 μg/kg to about 100 μg/kg of at least one vitamin D metabolite.6. The method according to claim 5 , wherein the vitamin D metabolite is 25-hydroxy vitamin D3.7. The method according to claim 6 , wherein canthaxanthin and 25-hydroxy vitamin D3 are administered together.8. A premix composition comprising 25-hydroxy vitamin D3 and canthaxanthin for use in breeder feed to improve hatchability. The present invention relates to the use of canthaxanthin and/or at least one vitamin D metabolite, preferably 25-hydroxy vitamin D3 (25-OH D3), for improved reproduction and performance of roosters. More particularly the invention relates to the use of canthaxanthin and/or 25-hydroxy vitamin D3 in the manufacture of a feed or veterinary composition for improving reproduction and performance of roosters.To ...

Подробнее

Номер записи: 58

30-05-2013 дата публикации

ANTICOAGULANT REVERSAL AGENTS

Номер: US20130137702A1

Автор: Bakhru Sasha H., Laulicht Bryan E., Mathiowitz Edith, Steiner Solomon S.

Принадлежит: Perosphere Inc.

Novel anticoagulant reversal compounds are disclosed, as well as methods of making the compounds, pharmaceutical compositions including the compounds, methods of using the compounds to reverse the anticoagulant effects of coagulation inhibitors, and diagnostic assays comprising the compounds. 1. A compound of formula I{'br': None, 'Y-M-X-L-A-L′-X′-M′-Y′\u2003\u2003(I)'}or a pharmaceutically acceptable salt thereof, wherein:A is a substituted or unsubstituted aromatic or non-aromatic, carbocyclic or heterocyclic ring or a linear moiety;L and L′ are the same or different and are linkers;X and X′ are the same or different and are absent or are a functional group that attaches the linker L to M and linker L′ to M′, respectively;M and M′ are the same or different and are absent or is a linker that attaches X to Y and X′ to Y′, respectively; andY and Y′ are the same or different and are a moiety containing one or more cationic atoms or groups or one or more groups that become cationic under physiological conditions.2. The compound of claim 1 , wherein A is a non-aromatic claim 1 , heterocyclic ring or a linear moiety claim 1 , and wherein the ring or the linear moiety contain reactive functional groups that can form a bond to X and/or X′ claim 1 , when present claim 1 , or Y and/or Y′.3. The compound of claim 2 , wherein A is a piperazine or diketopiperazine.43. The compound of any one of - claims 1 , wherein X and X′ claims 1 , when present claims 1 , is a functional group that attaches linker L to Y and linker L′ to Y′ claims 1 , respectively claims 1 , and wherein the functional group is selected from the group consisting of esters claims 1 , amides claims 1 , and ketones.54. The compound of any one of - claims 1 , wherein L and/or L′ is a substituted or unsubstituted alkylene chain that is Cto C.9. The compound of claim 8 , wherein G is amino.1615. A pharmaceutical composition comprising the compound of any one of - and a pharmaceutically acceptable carrier.17. The ...

Подробнее

Номер записи: 59

30-05-2013 дата публикации

Method for inhibiting histone gene transcription and expression

Номер: US20130137776A1

Автор: Cheng-Chia YU, Shih-Min HSIA, Tzong-Ming SHIEH

Принадлежит: CHINA MEDICAL UNIVERSITY

A method for inhibiting at least one of histone gene transcription and histone expression in a subject is provided. The method comprises administrating to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

Подробнее

Номер записи: 60

06-06-2013 дата публикации

COMPOSITION CONTAINING REDUCED COENZYME Q10, AND MANUFACTURING AND STABILISING METHODS THEREFOR

Номер: US20130142767A1

Автор: Kitamura Shiro, Ueda Yasuyoshi, YAMAGUCHI Takao

Принадлежит: Keneka Corporation

The present invention relates to a method of producing reduced coenzyme Q10, including reducing oxidized coenzyme Q10 using a reducing agent in terpenes that can highly dissolve oxidized coenzyme Q10 and reduced coenzyme Q10 in the co-existence of at least one kind of additive selected from the group consisting of alcohols, water, a surfactant and diacylglycerol. In addition, the present invention relates to a composition comprising terpenes, a reducing agent, reduced coenzyme Q10 and at least one kind selected from the group consisting of alcohols, water, a surfactant and diacylglycerol, and a method of stabilizing reduced coenzyme Q10 comprising preparing the composition. 1. A method of producing reduced coenzyme Q10 comprising , reducing oxidized coenzyme Q10 with a reducing agent in terpenes in the co-existence of at least one kind of additive selected from the group consisting of alcohols , water , a surfactant and diacylglycerol.2. The production method according to claim 1 , wherein the alcohol is a monovalent alcohol having 1 to 4 carbon atoms or a divalent alcohol having 2 to 4 carbon atoms.3. (canceled)4. (canceled)5. The production method according to claim 1 , wherein the terpene is at least one selected from the group consisting of hemiterpene claim 1 , monoterpene claim 1 , sesquiterpene claim 1 , diterpene claim 1 , sesterterpene and triterpene.6. The production method according to claim 1 , wherein the reducing agent is at least one selected from the group consisting of L-ascorbic acid claim 1 , D-arabo-ascorbic acid claim 1 , L-ascorbylpalmitate claim 1 , L-ascorbylstearate claim 1 , sodium borohydride claim 1 , sodium hydrosulfite claim 1 , retinal claim 1 , an acerola extract claim 1 , a pine bark extract claim 1 , a KOKIYO extract claim 1 , a gardenia pigment and a KOZU (fragrant vineger).7. The production method according to claim 1 , wherein the reduction reaction is performed in co-existence with fats claim 1 , oils or mixtures thereof8. ( ...

Подробнее

Номер записи: 61

06-06-2013 дата публикации

METHODS AND COMPOSITIONS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF BONE CANCER PAIN

Номер: US20130142882A1

Автор: Hwang San-Bao, Liu Sheng-Yung, Wen Wu-Che

Принадлежит: GOLDEN BIOTECHNOLOGY CORPORATION

The present invention provides methods and compositions for treating, preventing, modifying (reducing), or managing bone cancer pain by cyclohexenone compounds. 2. The method of claim 1 , which further comprises administering to the patient a therapeutically or prophylactically effective amount of at least one second active agent.3. The method of claim 2 , wherein the second active agent is capable of relieving or reducing pain.4. The method of claim 1 , wherein the bone cancer pain is from cancer originated in bone.5. The method of claim 1 , wherein the bone cancer pain is from osteosarcoma.6. The method of claim 1 , wherein the bone cancer pain is from cancer metastasized to bone.7. The method of claim 6 , wherein the bone cancer pain is from breast cancer claim 6 , prostate cancer claim 6 , lung cancer claim 6 , renal cancer claim 6 , liver cancer claim 6 , kidney cancer claim 6 , bladder cancer claim 6 , thyroid cancer claim 6 , cervical cancer claim 6 , or colon cancer metastasized to bone.8. The method of claim 6 , wherein the bone cancer pain is from esophageal cancer claim 6 , or nasopharyngeal cancer metastasized to bone.9. The method of claim 6 , wherein the bone cancer pain is from sarcoma metastasized to bone.10. The method of claim 7 , wherein the bone cancer pain is from breast cancer claim 7 , prostate cancer claim 7 , renal cancer claim 7 , or lung cancer claim 7 , metastasized to bone.11. The method of claim 2 , wherein the at least one second active agent is selected from the group consisting of an antidepressant claim 2 , antihypertensive claim 2 , anxiolytic claim 2 , calcium channel blocker claim 2 , muscle relaxant claim 2 , non-narcotic analgesic claim 2 , anti-inflammatory agent claim 2 , cox-2 inhibitor claim 2 , alpha-adrenergic receptor agonist claim 2 , alpha-adrenergic receptor antagonist claim 2 , ketamine claim 2 , anesthetic claim 2 , immunomodulatory agent claim 2 , immunosuppressive agent claim 2 , corticosteroid claim 2 , ...

Подробнее

Номер записи: 62

06-06-2013 дата публикации

CURCUMIN COMPOSITIONS AND USES THEREOF

Номер: US20130143969A1

Автор: Chen Wei, Chiu Ming Heung, Liu Zhongfa

Принадлежит: The Ohio State University

A composition and method of increasing the bioavailability of curcumin is provided. A synergistic combination of excipient polymers provides increased bioavailability thereby increasing the plasma concentration of curcumin and its metabolite curcumin O-glucuronide. The curcumin pharmaceutical compositions are suitable for modifying DNA methylation and treating diseases such as cancer. 1. A pharmaceutical composition comprising:curcumin, andat least two excipient polymers selected from the group consisting of a polyethoxylated castor oil, a polyoxyethylene sorbitan ester, and a polyethylene glycol (PEG).2. The composition of claim 1 , wherein the at least two excipient polymers are a polyethylene glycol and at least one of a polyethoxylated castor oil and a polyoxyethylene sorbitan ester.3. The composition of claim 1 , wherein the polyethylene glycol has an average molecular weight selected from the group consisting of 200 claim 1 , 300 claim 1 , 400 claim 1 , 500 claim 1 , 600 claim 1 , and combinations thereof claim 1 , and wherein the polyoxyethylene sorbitan ester is selected from polysorbate 20 claim 1 , 30 claim 1 , 40 claim 1 , 50 claim 1 , 60 claim 1 , 65 claim 1 , 70 claim 1 , 80 claim 1 , 85 claim 1 , and combinations thereof.4. The composition of claim 1 , wherein the polyethoxylated castor oil is the reaction product of 35 moles of ethylene oxide with each mole of castor oil.5. The composition of claim 1 , wherein a volume ratio of a polyethylene glycol to a second excipient polymer ranges from about 1:99 to about 99:1.6. The composition of claim 5 , wherein the second excipient polymer is the polyethoxylated castor oil and the volume ratio is about 4:1 to about 1:1.7. The composition of claim 5 , wherein the second excipient polymer is the polyoxyethylene sorbitan ester and the volume ratio is about 10:1 to about 1:1.8. The composition of claim 1 , wherein the composition is a gel having a curcumin concentration within the range of about 40 mg/mL to ...

Подробнее

Номер записи: 63

06-06-2013 дата публикации

Absorbable crystalline copolyester-based bioactive hydroforming luminal liner compositions

Номер: US20130144264A1

Автор: Georgios T. Hilas, Kenneth David Gray, Shalaby W. Shalaby

Принадлежит: Individual

Bioactive, hydroforming luminal liner compositions are formed of high molecular weight crystalline, absorbable copolyesters dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.

Подробнее

Номер записи: 64

13-06-2013 дата публикации

MEDICAL COMPOSITIONS CONTAINING LIQUORICE EXTRACTS WITH SYNERGISTIC EFFECT

Номер: US20130149393A1

Автор: Chen Dong, Zhou James

Принадлежит:

The invention provides drug compositions with synergistic effects, which includes alcohol-soluble and water-insoluble liquorices extracts and at least one kind of anti-tumor or glucose-and-lipid-lowering drug/eatable substance, and can be used to treat tumor or lower blood glucose and lipid. Besides, the invention also provides pharmaceutical preparation, pharmaceutical application, therapeutic and preparation methods, etc. related to this drug compositon. 1. Drug compositions with synergistic effects contain alcohol-soluble and water-insoluble liquorices extracts , and at least one kind of anti-tumor or glucose-or/and-lipid-lowering drug/eatable substances , and the preferred composition is composed of alcohol-soluble and water-insoluble liquorices extracts , and one kind of anti-tumor or glucose-and-lipid-lowering drug/eatable substance.2radix glycyrrhizaGlycyrrhiza uralensisglycyrrhiza inflataglycyrrhiza inflata.. The drug composition described in claim 1 , wherein liquorices are including or or their mixture claim 1 , the preferred is their mixture and the much more preferred is the mixture with more than 5%3. The drug compositions described in claim 1 , wherein alcohol-soluble and water-insoluble liquorices extracts are prepared through the methods including the following steps:(1) Reserve the solid parts after extraction of liquorices by water;(2) Reserve and dry the liquid part, after extracting the solid part by the extraction steps (1) with a high concentration alcohol (concentrations is higher than 85% (V/V), the preferred is higher than 90% (V/V), more preferred is higher than 93% ((V/V)), such as 95% (V/V)).4. The drug compositions described in claim 3 , wherein the described methods also include the step to further extract Chalcone A.5. The drug compositions described in claim 1 , wherein the content of liquorices flavonoid in alcohol-soluble and water-insoluble liquorices extracts is higher than 15% claim 1 , or the content of Chalcone A is higher than ...

Подробнее

Номер записи: 65

13-06-2013 дата публикации

Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome

Номер: US20130150346A1

Автор: BROTCHIE JONATHAN MICHAEL, Johnston Thomas Henry, Milne Todd G., Pearson James Philip

Принадлежит:

The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors to treat aspects of Parkinson's disease (PD), restless legs syndrome (RLS) and periodic limb movement disorder (PLMD), the use of FAAH inhibitors for the manufacture of medicaments for use in the treatment of PD, RLS and PLMD, as well as pharmaceutically acceptable compositions comprising FAAH inhibitors for use in the treatment of PD, RLS and PLMD. 182-. (canceled)83. A method of treating or preventing an impulse control disorder (ICD) , dopamine dysregulation syndrome (DDS) or sleep disorder arising from the treatment of a patient suffering from Parkinson's disease (PD) , restless legs syndrome (RLS) or periodic limb movement disorder (PLMD) or combination thereof with a dopaminergic agent , comprising administering a therapeutically effective amount of a FAAH inhibitor , or a therapeutically effective amount of a dopaminergic agent and a therapeutically effective amount of a FAAH inhibitor to said patient.84. The method according to claim 83 , wherein the dopaminergic agent is a dopamine replacement agent claim 83 , a dopamine agonist claim 83 , a dopamine uptake inhibitor or a monoamine oxidase inhibitor.85. The method according to claim 84 , wherein the dopamine replacement agent comprises melevodopa or L-3 claim 84 ,4-dihydroxyphenylalanine (levodopa claim 84 , L-DOPA) claim 84 , or an AADC enzyme inhibitor or both an AADC enzyme inhibitor and a COMT inhibitor.86. The method according to claim 85 , wherein the AADC enzyme inhibitor is carbidopa or benserazide and the COMT inhibitor claim 85 , if present claim 85 , is entacapone or tolcapone.87. The method according to claim 84 , wherein the dopamine agonist is bromocriptine (Parlodel®) claim 84 , pergolide (Permax®) claim 84 , pramipexole (Mirapex®) claim 84 , ropinirole (Requip®) claim 84 , rotigotine (Neupro®) claim 84 , cabergoline (Dostinex®) claim 84 , apomorphine (Apokyn®) claim 84 , lisuride (Dopergine®) or ...

Подробнее

Номер записи: 66

13-06-2013 дата публикации

Pharmaceutical composition comprising a curcumin derivative

Номер: US20130150628A1

Автор: Thomas M. DiMauro

Принадлежит: Individual

The present invention is directed to a pharmaceutical composition comprising:

Подробнее

Номер записи: 67

20-06-2013 дата публикации

COMPOSITION AND METHOD OF MANUFACTURE

Номер: US20130156746A1

Автор: Piraee Mahmood

Принадлежит: PERSAVITA LTD.

A dietary supplement composition includes a synergistic combination of saffron and resveratrol for providing anti-oxidant and gene modulation effects for preventing, ameliorating and/or reducing a rate of development and progression of age-related macular degeneration (AMD). Optionally, the combination is supplemented with one or more further ingredients: fish oil, Zinc, Copper, vitamin C, vitamin E, lutein, zeaxanthin. The combination is beneficially provided as a composition which is useful for reducing a risk of developing, and/or for reducing a rate of progression of age-related macular degeneration, and/or for preventing age-related sight loss, and other age-related diseases. 1. A composition for improving health , characterized in that said composition includes a combination of resveratrol and saffron.2. The composition as claimed in claim 1 , wherein said combination of resveratrol and saffron is implemented in a ratio of concentration of resveratrol: saffron powder being in a range of 1:1 to 100:1.3. The composition as claimed in claim 1 , wherein each dose of the composition includes in a range of 1 mg to 10000 mg resveratrol claim 1 , and in a range of 0.2 mg to 2000 mg saffron powder.4. The composition as claimed in claim 3 , wherein each dose of the composition includes in a range of 5 mg to 5000 mg resveratrol claim 3 , and in a range of 1 mg to 1000 mg saffron powder.5. The composition as claimed in claim 4 , wherein each dose of the composition includes in a range 50 mg to 700 mg resveratrol claim 4 , and in a range of 2 mg to 300 mg saffron powder.6. The composition as claimed in claim 5 , wherein each dose is a daily dose of the composition which includes substantially 100 mg resveratrol and substantially 20 mg saffron powder.7. The composition as claimed in claim 1 , wherein the saffron has a crocin content of at least 0.1% claim 1 , more preferably at least 1% claim 1 , and most preferably at least 10%.8. The composition as claimed in claim 1 , ...

Подробнее

Номер записи: 68

20-06-2013 дата публикации

PAIN RELIEF COMPOSITIONS, MANUFACTURE AND USES

Номер: US20130157985A1

Автор: Birbara Philip J., Bucks Daniel

Принадлежит: API Genesis, LLC

The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions. 1. A composition comprising:i) 0.075-30% by weight of a TRPV1 selective agonist, andii) 50-95% by weight of an analgesic agent comprising a) a topical salicylate and b) TRPM8 agonist or a TRPV3 agonist, capable of solubilizing said TRPV1 selective agonist,wherein said composition has an amount of TRPV1 selective agonist sufficient to decrease the density of functional nociceptive nerve fibers when said composition is applied topically, and said composition has an amount of analgesic agent sufficient to eliminate or reduce the burning and/or stinging sensation or erythema created by the topical administration of the TRPV1 selective agonist.2. A composition comprising:0.075-30% by weight of a TRPV1 selective agonist, and70-95% by weight of an analgesic agent capable of solubilizing said TRPV1 selective agonist,wherein said composition has an amount of TRPV1 selective agonist sufficient to decrease the density of functional nociceptive nerve fibers when said composition is applied topically, and said composition has an amount of analgesic agent sufficient to eliminate or reduce the burning and/or stinging sensation or erythema created by the topical administration of the TRPV1 selective agonist, and wherein said composition does not include turpentine oil.3. A composition as in or wherein said analgesic agent is a topical salicylate , a TRPM8 agonist , and a TRPV3 agonist.4. A composition as in or wherein the composition is a liquid solution.5. A composition as in comprising:i) 0.2-20% by weight of said TRPV1 selective agonist,ii) 50-95% by weight of said analgesic agent.6. A composition as in comprising:2-20% by weight of said TRPV1 selective agonist,50-95% by weight of said analgesic agent.7. A composition ...

Подробнее

Номер записи: 69

20-06-2013 дата публикации

Pharmaceutical compositions

Номер: US20130158077A1

Автор: Bjoern C. Kahrs

Принадлежит: ARES TRADING SA

The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.

Подробнее

Номер записи: 70

20-06-2013 дата публикации

METHODS AND COMPOSITIONS FOR TREATING BRAIN CANCER

Номер: US20130158113A1

Автор: Hwang San-Bao, Liu Sheng-Yung, Wen Wu-Che

Принадлежит: GOLDEN BIOTECHNOLOGY CORPORATION

The present invention provides methods and compositions for treating brain cancer by cyclohexenone compounds. 2. The method according to claim 1 , wherein said method reduces brain cancer tumor size or tumor growth rate.3. The method of claim 1 , wherein the brain cancer is neuroblastoma claim 1 , gliomas claim 1 , meningioma claim 1 , pituitary adenoma claim 1 , acoustic neuromas claim 1 , hemangiopericytoma claim 1 , hemangioblastoma claim 1 , multiple brain metastases claim 1 , glioblastoma claim 1 , medulloblastoma claim 1 , ependymoma claim 1 , craniopharyngioma claim 1 , germinoma claim 1 , pineoblastoma claim 1 , poor prognosis malignant brain tumor claim 1 , astrocytoma claim 1 , oligodendroglioma claim 1 , relapsed brain tumor claim 1 , or progressive brain tumor.4. The method according to claim 1 , wherein said compound induces cell death in said brain cancer.6. The method according to claim 5 , wherein said cell proliferative disorder of the brain is a precancerous condition or hyperplasia or metaplasia of the brain.7. The method according to any one of claim 1 , wherein said compound claim 1 , or a pharmaceutically acceptable salt claim 1 , metabolite claim 1 , solvate or prodrug thereof claim 1 , is administered parenterally claim 1 , intravenously claim 1 , or orally.8. The method of any one of claim 1 , wherein said subject is human.10. The method of claim 9 , wherein said brain cancer cells are human brain cancer cells.11. The method of claim 9 , wherein said cyclohexenone compound prevents or inhibits migration or invasion of the brain cancer cells.12. The method of any one of claim 1 , wherein R is a hydrogen claim 1 , C(═O)CH claim 1 , C(═O)CH claim 1 , or C(═O)CH.13. The method of any one of claim 1 , wherein each of R claim 1 , Rand Rindependently is a hydrogen claim 1 , methyl claim 1 , ethyl claim 1 , propyl claim 1 , butyl claim 1 , pentyl claim 1 , hexyl claim 1 , heptyl claim 1 , or octyl.14. The method of any one of claim 13 , wherein Ris ...

Подробнее

Номер записи: 71

27-06-2013 дата публикации

PHOSPHOLIPID AND PROTEIN TABLETS

Номер: US20130165393A1

Автор: Hoem Nils, Tilseth Snorre

Принадлежит: AKER BIOMARINE ASA

A new method for krill meal production has been developed using a two step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum. In the second stage the krill without phospholipids are cooked. Following this, residual fat and astaxanthin are removed from the krill using mechanical separation methods. A novel krill meal product with superior nutritional and technical properties is prepared. 1. A solid dosage form comprising an active ingredient in a concentration of greater than about 40% by weight of said dosage form , wherein said active ingredient is a protein-phospholipid composition comprising protein in a concentration of about 30% to about 50% by weight of said active ingredient and fat in a concentration of about 50% to about 75% by weight of said active ingredient , wherein said fat comprises phospholipids in a concentration of about 35% to about 60% by weight of said fat; and an adsorption agent; wherein said dosage form has a hardness of greater than about 60 N.2. The solid dosage form of claim 1 , wherein said protein-phospholipid composition is derived from krill.3. The solid dosage form of claim 1 , wherein said active ingredient further comprises astaxanthin.4. The solid dosage form of claim 3 , wherein said active ingredient comprises from about 1 to about 200 mg/kg astaxanthin5. The solid dosage form of claim 1 , wherein said fat comprises omega-3 fatty acids residues in a concentration of from about 10% to about 35% by weight of said fat.6. The solid dosage form of claim 1 , wherein said phospholipids comprise phosphatidylcholine in a concentration of greater than about 65% by weight of said phospholipids.7. The solid dosage form of claim 1 , wherein said phospholipids comprise alkylacylphosphatidylcholine in a concentration of from about 2% to about 10% by weight of said phospholipids.8. The solid dosage form of claim 1 , said adsorption agent is provided in a concentration of ...

Подробнее

Номер записи: 72

27-06-2013 дата публикации

NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS

Номер: US20130165495A1

Автор: El Sayed Khalid, Eterovic De Ferchmin Vesna Ana, Ferchmin Peter Andrew, Maldonado Hector Manuel

Принадлежит:

A method of inhibiting excitotoxicity by indirectly activating α4β2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed Inhibitors of α7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate α4β2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis. 2. A method of wherein Ris α—OH and R claim 1 , R claim 1 , R claim 1 , and Rare H3. A method of wherein Ris OH and R claim 1 , R claim 1 , R claim 1 , and Rare H4. A method of wherein Ris β—OH and R claim 1 , R claim 1 , R claim 1 , and Rare H5. A method of wherein Ris OH and R claim 1 , R claim 1 , R claim 1 , and Rare H12. The method of wherein said compound is administered in an amount sufficient to achieve a concentration between about 200 nM to about 40 μM.13. The method of wherein said compound is administered in an amount sufficient to achieve a concentration between about 200 nM to about 40 μM.14. The method of wherein said compound is administered in an amount sufficient to achieve a concentration between about 200 nM to about 40 μM.15. The method of wherein said compound is administered in an amount sufficient to achieve a concentration between about 200 nM to about 40 μM.16. The method of wherein said compound is administered in an amount sufficient to achieve a concentration between about 200 nM to about 40 μM.17. The method of wherein said compound is administered in an amount sufficient to achieve a concentration between about 200 nM to about 40 μM.18. The method of wherein said compound is administered in an amount sufficient to achieve a ...

Подробнее

Номер записи: 73

04-07-2013 дата публикации

VITAMIN CONTAINING PRODUCT

Номер: US20130172423A1

Автор: QUINLAN Paul Thomas, VERMEER Cees

Принадлежит: NATTOPHARMA ASA

A food product comprising menaquinone at a level of 50 to 5,000 μg per 100 g of product. 1. A method for maintaining , optimising , strengthening or promoting cardiovascular health of an individual , comprising providing a food product which is not an egg , wherein an amount of menaquinone has been added to the food product such that the level of menaquinone is 5 to 5000 μg per 100 g of product , with the proviso that if the menaquinone is a MK-n menaquinone , wherein n≧4 , then the food product is not a cheese or natto.2. A method according to claim 1 , wherein the food product is not a highly proteinaceous food product such as meat claim 1 , fish claim 1 , or dairy product.3. A method according to claim 1 , wherein the food product is selected from the group of meal replacers claim 1 , dietary supplements claim 1 , ice-cream claim 1 , sauces claim 1 , dressing claim 1 , spreads claim 1 , bars claim 1 , sweets claim 1 , snacks claim 1 , cereals and beverages.4. A method according to claim 1 , wherein the menaquinone level is from 5 to 100 μg per 100 g product.5. A method according to claim 1 , wherein the menaquinone is a MK-4 menaquinone.6. A method according to claim 1 , wherein the menaquinone is a MK-n menaquinone and n is greater than 4.7. A method according to claim 1 , wherein the food product further comprises one or more of calcium claim 1 , vitamin D or magnesium.8. A method according to claim 1 , wherein the individual is a human.9. A method for maintaining claim 1 , optimising claim 1 , strengthening or promoting cardiovascular health of an individual claim 1 , comprising providing a food product which is not an egg claim 1 , cheese or natto claim 1 , and adding menaquinone to the food product so that the total amount of vitamin K in the food product consists essentially of menaquinone in an amount of 5 to 5000 μg per 100 g of product.10. A method for maintaining claim 1 , optimising claim 1 , strengthening or promoting cardiovascular health of an ...

Подробнее

Номер записи: 74

11-07-2013 дата публикации

Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease

Номер: US20130178522A1

Автор: Deborah R. Neal, James M. JAMISON, Karen M. Mcguire, Mark William Kovacik, Michael John Askew, Nicholas F. LaRusso, Richard Albert Mostardi, Tetyana V. Masyuk, Thomas M. Miller

Принадлежит: Mayo Foundation for Medical Education and Research, Summa Health Systems LLC

Provided herein is a pharmaceutical composition comprising vitamin C and chromium-free vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Also provided herein is a chromium-free pharmaceutical composition comprising vitamin C and vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Further provided herein is a method of treating, preventing, or managing an NFKB-mediated condition, disorder, or disease, comprising administering to the subject a therapeutically effective amount of vitamin C and chromium-free vitamin K.

Подробнее

Номер записи: 75

18-07-2013 дата публикации

Silicone scar treatment preparation

Номер: US20130183256A1

Автор: Paul Guilbaud

Принадлежит: Advanced Bio Technologies Inc

Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives.

Подробнее

Номер записи: 76

18-07-2013 дата публикации

NUTRIENT COMPOSITIONS AND METHODS FOR ENHANCED EFFECTIVENESS OF THE IMMUNE SYSTEM

Номер: US20130183277A1

Автор: Kaiser Jon D.

Принадлежит:

Provided are compositions and methods for increasing patient CD4+ cell count while undergoing treatment for immune-mediated disease, cancer, heart disease, neurodegenerative disease, or infectious disease by administering to the patient a nutrient composition including, inter alia, alpha lipoic acid, acetyl L-carnitine, and N-acetyl-cysteine. 127-. (canceled)28. A method of increasing a mammal's CD4+ cell count while undergoing therapy for treatment of a condition selected from the group consisting of immune-mediated diseases , cancer , heart disease , neurodegenerative disease , and infectious disease , comprising:administering to the mammal, during a treatment period, a nutrient composition and at least one drug effective for treatment of said condition; 1.43 mg to 11.42 mg alpha lipoic acid;', '3.57 mg to 28.58 mg acetyl L-carnitine; and', '4.28 mg to 34.28 mg N-acetyl-cysteine;, 'the nutrient composition comprising, in per kg body weight per daywhereby the mammal's CD4+ cell count is increased during the treatment period.29. The method of claim 28 , wherein the nutrient composition further comprises one or more vitamins or minerals selected from the group consisting of zinc claim 28 , selenium claim 28 , vitamin C claim 28 , bioflavinoid complex claim 28 , vitamin E claim 28 , beta-carotene claim 28 , vitamin A claim 28 , vitamin B1 claim 28 , vitamin B2 claim 28 , vitamin B6 claim 28 , niacinamide claim 28 , calcium panthothenate claim 28 , folic acid claim 28 , vitamin B12 claim 28 , copper claim 28 , manganese claim 28 , chromium claim 28 , and molybdenum;30. The method of claim 28 , wherein the alpha-lipoic acid claim 28 , acetyl L-carnitine claim 28 , and N-acetyl-cysteine are present in the nutrient composition in a ratio from 1:1:1 to 1:4:6.31. The method of claim 28 , wherein the treatment period is from about three to about twelve weeks.32. The method of claim 28 , wherein the treatment period is at least fifteen weeks.33. The method of claim 28 , ...

Подробнее

Номер записи: 77

18-07-2013 дата публикации

Methods and compositons for cell-proliferation-related disorders

Номер: US20130183281A1

Автор: Lenny Dang, Shengfang Jin, Shin-San Michael Su, Stefan Gross, Valeria Fantin

Принадлежит: Agios Pharmaceuticals Inc

Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).

Подробнее

Номер записи: 78

18-07-2013 дата публикации

Cytochrome P450 2C9 Inhibitors

Номер: US20130184227A1

Автор: HSIONG Cheng-Huei, HU Oliver Yoa-Pu, PAO Li-Heng, Wang Hong-Jaan

Принадлежит:

This invention is to provide multiple specific inhibitors of cytochrome P450 isozyme CYP2C9. These inhibitors can be derived from any combinations with the following compounds including: Tamarixetin, Formononetin, isoliquritigenin, Phloretin, luteolin, Quercitrin, quercetin, myricetin, Wongonin, Puerarin, Genistein, Nordihydroguaiaretic acid, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, 6-Gingerol, Isorhamneti, isoquercitrin, Morin, (+)-Taxifolin, isovitexin, 3-Phenylpropyl Acetate, Oleanolic acid, ursolic acid, β-Myrcene, cinnamic acid, Luteolin-7-Glucoside, Liquiritin, (+) Limonene, Homoorientin, Swertiamarin, Embelin, Daidzein, Poncirin, (−)-Epicatechin, ergosterol. These natural products can be used to enhance the bioavailability of therapeutic agents (drugs). 1. A method for enhancing the bioavailability of a therapeutic agent in a patient comprising:administering a pharmaceutically effect amount of CYP2C9 inhibitor and a pharmaceutically viable drug extensively metabolized by CYP2C9 to said patient in need thereof,wherein said CYP2C9 inhibitor which is selected at least one compound of the following group consisting of Tamarixetin, Formononetin, luteolin, Quercitrin, myricetin, Wongonin, Puerarin, Genistein, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, Isorhamnetin, isoquercitrin, Morin, (+)-Taxifolin, isovitexin, Luteolin-7-Glucoside, Daidzein, and Poncirin; andwherein said pharmaceutically viable drug which is one selected from the group consisting of tolbutamide, diclofenac, warfarin, phenytoin, torsemide, fluvastatin, losartan, celecoxib, meloxicam, isoniazide, valproic acid, ibuprofen, carvedilol, naproxen, and ondansetron.2. A method for enhancing the bioavailability of a therapeutic agent in a patient comprising:administering a CYP2C9 inhibitor and a pharmaceutically viable drug extensively metabolized by CYP2C9 to said patient in need thereof,wherein said CYP2C9 inhibitor is Phloretin; andwherein said pharmaceutically viable drug ...

Подробнее

Номер записи: 79

25-07-2013 дата публикации

CO-ENZYME Q10 FORMULATIONS AND METHODS OF USE

Номер: US20130189237A1

Автор: Hsia Sung Lan, Li Jie, NARAIN Niven Rajin, Persaud Indushekhar, Russell Kathryn J., Woan Karrune V.

Принадлежит: UNIVERSITY OF MIAMI

Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals. 17-. (canceled)8. A method of treating a pancreatic tumor in a subject , comprising intravenously administering to the subject a composition comprising 1% to 20% w/w of Coenzyme Q10 in an amount effective and for a sufficient time to reduce the growth of the pancreatic tumor , thereby treating the pancreatic tumor in the subject.9. The method of claim 8 , wherein the composition comprises 1% to 10% w/w of Coenzyme Q10.10. The method of claim 8 , wherein the composition comprises 1% to 5% w/w of Coenzyme Q10.11. (canceled)12. The method of claim 8 , wherein a the Coenzyme Q10 composition is administered with an additional anti-cancer agent.1336-. (canceled)37. The method of claim 8 , comprising intravenously administering Coenzyme Q10 by continuous infusion.38. The method of claim 12 , wherein the additional anti-cancer agent is co-administered with the composition comprising Coenzyme Q10 to the subject.39. The method of claim 12 , wherein administration of the additional anti-cancer agent precedes administration of the composition comprising Coenzyme Q10 to the subject.40. The method of claim 12 , wherein administration of the additional anti-cancer agent follows administration of the composition comprising Coenzyme Q10 to the subject.41. The method of claim 12 , wherein the additional anti-cancer agent is an anti-angiogenic agent.42. The method of claim 12 , wherein the additional anti-cancer agent is a chemotherapeutic agent.43. The method of claim 42 , wherein the chemotherapeutic agent is selected from the group consisting of cyclophosphamide claim 42 , taxanes claim 42 , busulfan claim ...

Подробнее

Номер записи: 80

25-07-2013 дата публикации

Nanoemulsion composition containing vitamin k

Номер: US20130189316A1

Автор: Andrew Xian Chen

Принадлежит: Latitude Pharmaceuticals Inc

In certain embodiments, this invention sets forth compositions, methods, and uses regarding a nanoemulsion composition that comprises a fat-soluble vitamin K and can therapeutically replace Phytonadione Injectable Emulsion, USP.

Подробнее

Номер записи: 81

01-08-2013 дата публикации

EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF

Номер: US20130196012A1

Автор: Dill David A.

Принадлежит: WELLESLEY PHARMACEUTICALS, LLC

Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. 1. A method for reducing the frequency of urination in a subject , comprising:administering to a subject in need thereof a pharmaceutical composition comprising:an active ingredient comprising one or more analgesic agents in an amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen,wherein said pharmaceutical composition is formulated for extended-release such that said active ingredient is released continuously over a period of 5-24 hours.2. The method of claim 1 , wherein said one or more analgesic agents comprises acetaminophen.3. The method of claim 1 , wherein said active ingredient further comprises an antimuscarinic agent.4. The method of claim 1 , wherein said active ingredient further comprises an antidiuretic agent.5. The method of claim 1 , wherein said active ingredient further comprises a spasmolytic.6. The method of claim 1 , wherein said active ingredient further comprises zolpidem.7. The method of claim 1 , wherein said an active ingredient further comprises two additional agents selected from the group consisting of an antimuscarinic agent claim 1 , an antidiuretic agent claim 1 , a spasmolytic and zolpidem.8. The method of claim 1 , wherein said pharmaceutical composition is formulated for extended-release such that said active ingredient is released continuously over a period of 5-8 hours.9. The method of claim 1 , wherein said pharmaceutical ...

Подробнее

Номер записи: 82

01-08-2013 дата публикации

Extended-release formulation for reducing the frequency of urination and method of use thereof

Номер: US20130196956A1

Автор: David A. Dill, Ilya A. Volfson

Принадлежит: Wellesley Pharmaceuticals LLC

A method for reducing the frequency of urination is disclosed. The method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents and one or more α-blockers. In one embodiment, the one or more analgesic agents are formulated for extended-release.

Подробнее

Номер записи: 83

08-08-2013 дата публикации

Treatment of Neurocutaneous Syndrome, Including Compositions, Methods and Uses Thereof

Номер: US20130202570A1

Автор: Omar M. Amin

Принадлежит: Individual

A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof.

Подробнее

Номер записи: 84

08-08-2013 дата публикации

Autotaxin pathway modulation and uses thereof

Номер: US20130202614A1

Автор: Vassilios Aidinis

Принадлежит: B S R C "ALEXANDER FLEMING"

Disclosed are methods for preventing, treating, or reducing symptoms of a disorder involving the autotaxin (ATX) pathway. In one embodiment, the method features administering to a mammal a sufficient amount of an autotaxin (ATX) or lysophosphatidic acid (LPA) signaling inhibitor, to prevent, treat or reduce symptoms of an inflammatory disorder, autoimmune disorder, fibrosis or malignancy of the lung. Further disclosed are methods for diagnosing an autotaxin-related disorder as well as kits for performing the methods of the invention.

Подробнее

Номер записи: 85

08-08-2013 дата публикации

Treatment of Neurocutaneous Syndrome, Including Compositions, Methods and Uses Thereof

Номер: US20130202722A1

Автор: Omar M. Amin

Принадлежит: Individual

A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof.

Подробнее

Номер записи: 86

08-08-2013 дата публикации

Method for Stimulating the Reproductive Capacity in a Bull, and Composition for Stimulating the Reproductive Capacity in a Bull

Номер: US20130203844A1

Автор: Briant Christine, Chemineau Philippe, Gerard Olivier, Humblot Patrice, Le Danvic Chrystelle, Meillour Patricia

Принадлежит:

The invention relates to the use of a composition comprising at least one volatile molecule specific to the estrus of cows in order to improve the reproductive function of a bull. In particular, the composition according to the invention makes it possible to act on the libido of the bull, but also on the production of semen by the bull. Preferably, the composition used comprises at least one molecule from among coumarin, squalene, 6-amino undecane, 2-butanone, 9-octadecenoic acid and 1,2-dichloroethylene. 119.-. (canceled)20. A method to improve the reproductive function of a bull which comprises administering to the bull a composition comprising at least one volatile molecule specific to the estrus of cows which is selected from the group consisting of coumarin , squalene , 6-amino undecane , 2-butanone , 9-octadecenoic acid , 1 ,2-dichloroethylene and mixtures thereof.211. The method of claim wherein improving reproductive function includes improving the bull's libido.221. The method of claim wherein improving reproductive function includes improving the production of semen by the bull.231. The method of claim wherein the composition is in the form of a solution comprising at least glycerol as a solvent of the volatile molecules.241. The method of claim wherein the total concentration of the at least one molecule specific to estrus in the composition is between 2.5 pg/mL and 500 pg/mL.251. The method of claim wherein the total concentration of the at least one molecule specific to estrus in the composition is between 100 pg/mL and 500 pg/mL.261. The method of claim wherein the concentration of the at least one molecule specific to the estrus in the composition is at least equal to 25 pg/mL , +/−5%.271. The method of claim wherein the composition comprises a mixture of two or more of volatile molecules selected from the group consisting of coumarin , squalene , 6-amino undecane , 2-butanone , 9-octadecenoic acid , and 1 ,2-dichloroethylene.281. The method of claim ...

Подробнее

Номер записи: 87

15-08-2013 дата публикации

NEW USES

Номер: US20130209386A1

Автор: Cove Jonathan, Fitzgerald Daniel, Read Nicholas

Принадлежит: EVOCUTIS PLC

An antibacterial or anti-acne formulation containing (a) tropone or a substituted tropone and (b) a metal or metal salt selected from copper, copper salts, bismuth, bismuth salts, silver, silver salts, and mixtures thereof, for use in the treatment of either acne or body odour. The substituted tropone may be for example tropolone or hinokitiol. 115-. (canceled)16. A method of treating a human or animal patient suffering from or at risk of suffering from either acne or body odour , the method involving administering to the patient a therapeutically effective amount of a formulation containing (a) tropone or a substituted tropone and (b) a metal or metal salt selected from copper , copper salts , bismuth , bismuth salts , silver , silver salts , and mixtures thereof.17. The method of claim 16 , wherein the tropone (a) is tropolone.18. The method of claim 16 , wherein the component (b) comprises a copper salt.19. The method of claim 16 , wherein the component (b) comprises a bismuth salt.20. The method of claim 16 , wherein the component (b) comprises a silver salt.21. The method of claim 16 , wherein the patient is suffering from or at risk of suffering from acne.22. The method of claim 16 , wherein the patient is suffering from or at risk of suffering from body odour.23. The method of claim 16 , wherein the formulation is administered topically.24. A method of skin care treatment for non-therapeutic purposes claim 16 , the method involving applying to the skin a formulation containing (a) tropone or a substituted tropone and (b) a metal or metal salt selected from copper claim 16 , copper salts claim 16 , bismuth claim 16 , bismuth salts claim 16 , silver claim 16 , silver salts claim 16 , and mixtures thereof.25. A method for controlling the growth of a bacterium claim 16 , the method comprising applying claim 16 , to an area or surface which is infected or suspected to be infected or capable of becoming infected with the bacterium claim 16 , a formulation ...

Подробнее

Номер записи: 88

15-08-2013 дата публикации

AGENT FOR INHIBITING ODOR OF PYRAZINE DERIVATIVES

Номер: US20130210775A1

Автор: Inoue Michiaki, KATO Aya, Nomizu Kayoko, Saito Naoko

Принадлежит: KAO CORPORATION

Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient. 1. A method of reducing an odor of a pyrazine derivative , wherein the method comprises coexisting an odor of a pyrazine derivative with at least one compound selected from the group consisting of the following compounds:2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol;5-methyl-2-(1-methylethyl)-phenol;3,7-dimethyl-2,6-octadienal;phenylethyl salicylate;1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2-naphthalenyl)-ethanone;isolongifolanone;4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one (α-ionone);4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-one (β-ionone);vetiverol;7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7-tetramethyl-naphthalene;α-amylcinnamic aldehyde;α-methyl-4-(1-methylethyl)-benzenepropanal;4-methyl-3-decen-5-ol;1-(2-tert-butylcyclohexyloxy)-2-butanol;2-methoxy-1-(phenylmethoxy)-4-(1-propenyl)-benzene;α-methyl-β-(p-tert-butylphenyl)-propionaldehyde;l(−)-menthol;ω-6-hexadecenelactone;2-(2-(4-methyl)-3-cyclohexen-1-yl)-propylcyclopentanone;formaldehyde cyclododecyl ethyl acetal;1-(2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-1H-3a,7-methanoazulen-5-yl)-ethanone;β-methyl naphthyl ketone;cedryl acetate;(5E)-3-methylcyclopenta-5-decen-1-one;cinnamaldehyde;4-(1-ethoxyvinyl)-3,3,5,5-tetramethylcyclohexanone;α-hexylcinnamic aldehyde;2-phenylpropionaldehyde;3,7-dimethyl-6-octenal;dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1-b]furan;4,7,7-trimethyl-spirobicyclo[2.2.1]heptane-2,1-cyclopentan-3-one;α-isomethyl ionone;3,7-dimethyl-1-octanol;cedryl methyl ether;muscone;2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol;2-cyclohexylpropanal;γ-undecalactone;cyclopentadecanolide;1-(2,6,6-trimethyl-1,3-cyclohexadien-1-yl)-2-buten-1-one;2,4-dimethyl-3-cyclohexene-1-carboxyaldehyde;2,4,6-trimethyl-3-cyclohexene-1- ...

Подробнее

Номер записи: 89

15-08-2013 дата публикации

GLYCYRRHETINIC ACID DERIVATIVES

Номер: US20130210926A1

Автор: Chintharlapalli Sudhakar, McAlees Alan, McCrindle Robert, Safe Stephen H.

Принадлежит:

The present invention relates to novel derivatives of glycyrrhetinic acid, compositions comprising said derivatives and their use in the treatment of conditions or diseases that benefits from an upregulation of PPARγ and/or a downregulation of the expression or activity of one or more specificity (Sp) proteins, such as cancer, diabetes and Huntington's disease. 2. The method according to claim 1 , wherein Ris selected from CN claim 1 , halo claim 1 , NO claim 1 , COH claim 1 , COCalkyl claim 1 , Calkyl claim 1 , fluoro-substituted Calkyl claim 1 , Calkenyl claim 1 , Calkynyl claim 1 , OCalkyl claim 1 , fluoro-substituted OCalkyl claim 1 , OH claim 1 , SH claim 1 , SCalkyl claim 1 , SOCalkyl claim 1 , SOCalkyl claim 1 , NH claim 1 , NHCalkyl claim 1 , N(Calkyl)(Calkyl) claim 1 , C(O)NH claim 1 , C(O)NHCalkyl claim 1 , C(O)N(Calkyl)(Calkyl) claim 1 , C(O)Calkyl claim 1 , OC(O)Calkyl and NHC(O)Calkyl.3. The method according to claim 2 , wherein Ris selected from CN claim 2 , halo claim 2 , COH claim 2 , COCalkyl claim 2 , Calkyl claim 2 , fluoro-substituted Calkyl claim 2 , OCalkyl claim 2 , fluoro-substituted OCalkyl and OH.4. The method according to claim 3 , wherein Ris selected from CN claim 3 , Cl claim 3 , Br claim 3 , I claim 3 , F claim 3 , COH claim 3 , COCH claim 3 , CH claim 3 , CF claim 3 , OCH claim 3 , OCFand OH.5. The method according to claim 4 , wherein Ris CN claim 4 , CFor I.6. The method according to claim 1 , wherein Ris selected from OCalkyl claim 1 , fluoro-substituted OCalkyl claim 1 , NH claim 1 , NHCalkyl claim 1 , N(Calkyl)(Calkyl) claim 1 , SH and SCalkyl.7. The method according to claim 6 , wherein Ris selected from OCalkyl and fluoro-substituted OCalkyl.8. The method according to claim 7 , wherein Ris selected from OCHCH claim 7 , OCHand OCF.9. The method according to claim 8 , wherein Ris OCH.12. The method according to claim 1 , wherein the compound is selected from:2-cyano-3,11-dioxo-18β-oleana-1,12-dien-30-oic acid methyl ester;2-cyano ...

Подробнее

Номер записи: 90

22-08-2013 дата публикации

STABLE AQUEOUS SUSPENSION

Номер: US20130216512A1

Автор: Milley Christopher J., Peters Scott E.

Принадлежит:

An aqueous suspension of a hydrophobic nutrient is disclosed, in particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension. 1. An aqueous suspension of a hydrophobic nutrient which comprises ,the nutrient in ester form associated with a dispersion aid selected from the group consisting of a triglyceride, an essential oil extractive, night primrose oil, fish oil, and a mixture of any of the foregoing dispersion aids;a dispersion agent: andan aqueous medium into which said associated nutrient is suspended.2. The suspension as defined in claim 1 , wherein said associated nutrient is in a fully dispersed claim 1 , uniform form in the aqueous medium.3. The suspension as defined in claim 2 , wherein the particles size of said fully dispersed claim 2 , uniform form ranges from 50 to 400 nm.4. The suspension as defined in claim 1 , wherein said ester is an ester of a nutritional compound selected from the group consisting of (a) a phytosterol selected from the group consisting of stigmasterol claim 1 , sitosterol claim 1 , fucosterol claim 1 , brassieasterol claim 1 , campesterol claim 1 , clionasterol claim 1 , desmosterol claim 1 , chalinosterol claim 1 , poriferasterol claim 1 , and any mixture of the foregoing phytosterols; (b) a phytostanol claim 1 , selected from the group consisting of e.g. α sitostanol or β sitostanol claim 1 , campestanol claim 1 , brassieastanol claim 1 , clionastanol claim 1 , stigmastanol claim 1 , desmostanol claim 1 , chalinostanol claim 1 , poriferastanol claim 1 , 22 claim 1 , 23 dihydrobrassieastanol and any mixture of the foregoing phytostanols; (c) lutein claim 1 , (d) Coenzyme Q claim 1 , (e) isoflavones claim 1 , (f) and a mixture of any of the foregoing esters.5. The suspension as defined in claim 1 , wherein said triglyceride is selected from the group consisting of sunflower oil claim 1 , soy bean oil claim 1 , olive ...

Подробнее

Номер записи: 91

22-08-2013 дата публикации

EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF

Номер: US20130216620A1

Автор: Dill David A.

Принадлежит: WELLESLEY PHARMACEUTICALS, LLC

Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release. 128-. (canceled)29. A method for reducing the frequency of urination , comprising:administering to a subject in need thereof a pharmaceutical composition comprising acetaminophen formulated in an extended-release formulation, wherein said acetaminophen is administered orally at a daily dose of 5 mg to 2000 mg.30. The method of claim 29 , wherein said acetaminophen is administered orally at a daily dose of 50 mg to 500 mg.31. The method of claim 29 , wherein said acetaminophen is administered orally at a daily dose of 100 mg to 500 mg.32. The method of claim 29 , wherein said acetaminophen is administered orally at a daily dose of 250 mg to 500 mg.33. The method of claim 29 , wherein said acetaminophen is administered orally at a daily dose of 250 mg to 1000 mg.34. The method of claim 29 , wherein said acetaminophen is administered orally at a daily dose of 5 mg to 100 mg.35. The method of claim 34 , wherein said acetaminophen is administered orally at a daily dose of 10 mg to 50 mg.36. The method of claim 34 , wherein said pharmaceutical composition further comprises an antimuscarinic agent selected from the group consisting of oxybutynin claim 34 , solifenacin claim 34 , darifenacin and atropine.37. The method of claim 34 , wherein said pharmaceutical composition further ...

Подробнее

Номер записи: 92

22-08-2013 дата публикации

CIS 3,4-DIHYDROXY-2-(3-METHYLBUTANOYL)-5-(3-METHYLBUTYL)-4-(4-METHYLPENTANOYL)CYCLOPENT-2-EN-1-ONE DERIVATIVES, SUBSTANTIALLY ENANTIOMERICALLY PURE COMPOSITIONS AND METHODS

Номер: US20130217781A1

Автор: CARROLL Brian J., DAHLBERG Clinton J., DARLAND Gary, DESAI Anuradha, KONDA Veera, URBAN Jan

Принадлежит: KINDEX THERAPEUTICS, LLC

The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (−)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, activate GPR120, inhibit inflammation, and treat conditions responsive to PPARγ modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes. 2. A method of treating diabetes in a subject in need thereof comprising administering a therapeutically effective amount of a substantially enantiomerically pure composition of (+)-(4S , 5R)-3 ,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one potassium salt.3. A method of treating a condition responsive to PPARγ modulation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a substantially enantiomerically pure composition of (+)-(4S ,5R)-3 ,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one potassium salt.4. The method of or , wherein the substantially enantiomerically pure composition further comprises a pharmaceutically acceptable carrier.5. The method of or wherein the enantiomerical purity of (+)-(4S ,5R)-3 ,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one potassium salt is 98% or higher.6. The method of wherein the enantiomerical purity of (+)-(4S claim 5 ,5R)-3 claim 5 ,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one potassium salt is 99% or higher.7. The method of wherein the ...

Подробнее

Номер записи: 93

22-08-2013 дата публикации

Compounds and pharmaceutical compositions thereof for inhibiting mammalian tumor cell proliferation

Номер: US20130217902A1

Автор: Hsin-Ling Yang, You-Cheng Hseu

Принадлежит: CHINA MEDICAL UNIVERSITY

Compounds of following general formula (I) and pharmaceutical compositions thereof for inhibiting mammalian tumor cell proliferation are disclosed. In formula (I), n is an integer from 0 to 9. The cell proliferation of breast tumor, ovarian tumor, skin tumor or liver tumor is inhibited by the compounds of the formula (I).

Подробнее

Номер записи: 94

22-08-2013 дата публикации

Novel treatment of prostate carcinoma

Номер: US20130219528A1

Автор: Per Borgstrom

Принадлежит: Pellficure Pharmaceuticals Inc

Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

Подробнее

Номер записи: 95

29-08-2013 дата публикации

METHODS OF TREATING BEHAVIORAL SYMPTOMS OF NEUROLOGICAL AND MENTAL DISORDERS

Номер: US20130224172A1

Автор: Fallon James J., Fallon Joan M., HEIL Matthew F., NANUS Kenneth, SZIGETHY James

Принадлежит: CUREMARK, LLC

Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders, neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders. Also disclosed herein are products for use in methods of treatment and methods of making the same. 1. A method of treating a subject with one or more symptoms of an ASD , comprising:administering to the subject a pharmaceutical composition comprising one or more excipients and a therapeutic composition, wherein the therapeutic composition comprises protease, amylase and/or lipase,wherein the subject exhibits improvement in one or more symptoms of an ASD comprising:(a) protein intake, fat intake, carbohydrate intake, vitamin intake, diarrhea, constipation, seizures, and/or bone fragility; and/or(b) hyperactivity, irritability, agitation, obsessive compulsive behavior, eye contact, speech, lethargy, hypersensitivity, stereotypy, toilet training, non-compliance, inattention, aggression, impulsivity, conduct disorder, or oppositional defiance and/or social withdrawal and wherein the subject has a greater improvement in the one or more symptoms of an ASD after administration of the pharmaceutical composition than a subject a subject with one or more symptoms of an ASD administered a placebo.23-. (canceled)4. The method of claim 1 , wherein the subject exhibits a 10% or greater improvement in one or more symptoms of an ASD after administration of the pharmaceutical composition in comparison to before the subject was administered the pharmaceutical composition.58-. (canceled)9. The method of claim 1 , wherein the greater the amount of daily protein claim 1 , fat claim 1 , carbohydrate and/or vitamin intake (by weight) consumed by the subject after administration of ...

Подробнее

Номер записи: 96

29-08-2013 дата публикации

METHODS AND COMPOSITIONS FOR TREATING POX VIRUS INFECTIONS

Номер: US20130224286A1

Автор: Hügin Ambros

Принадлежит:

Human viral infections can cause lesions of the skin and/or mucous membranes. Provided herein are 1,4-naphthoquinone family compounds which are useful in the treatment of these lesions. Further provided herein are pharmaceutical compositions comprising a 1,4-naphthoquinone family compound and methods of using such compositions in the treatment of these lesions. 1Molluscum contagiosum virus.. A pharmaceutical composition comprising a therapeutically effective amount of a 1 ,4-naphthoquinone family compound for treating a subject having a viral induced lesion of the skin and/or mucous membranes caused by2. The pharmaceutical composition according to claim 1 , wherein said 1 claim 1 ,4-naphthoquinone family compound is selected from the group consisting of Menadione claim 1 , Naphthoquinone claim 1 , Lawsone claim 1 , Juglone claim 1 , and Plumbagin; or a salt thereof.3. The pharmaceutical composition of claim 2 , wherein the Menadione salt is selected from the group consisting of menadione bisulfite claim 2 , menadione dimethylpyrimidol bisulphite claim 2 , menadione sodium bisulfite claim 2 , Menadione nicotinamide bisulfite claim 2 , Menadione disphosphate tetrasodium salt claim 2 , Menadione sodium phosphate claim 2 , Menadione pyridinol bisulfite claim 2 , menadione epoxide claim 2 , and menadione sodium bisulfite trihydrate.4. The pharmaceutical composition of claim 2 , wherein the Naphthoquinone salt is selected from the group consisting of Naphthoquinone bisulfite claim 2 , Naphthoquinone dimethylpyrimidol bisulphite claim 2 , Naphthoquinone sodium bisulfite claim 2 , Naphthoquinone nicotinamide bisulfite claim 2 , Naphthoquinone disphosphate tetrasodium salt claim 2 , Naphthoquinone sodium phosphate claim 2 , Naphthoquinone pyridinol bisulfite claim 2 , Naphthoquinone epoxide claim 2 , and Naphthoquinone sodium bisulfite trihydrate.5. The pharmaceutical composition of claim 2 , wherein the Lawsone salt is selected from the group consisting of Lawsone bisulfite ...

Подробнее

Номер записи: 97

29-08-2013 дата публикации

Therapeutic Compounds

Номер: US20130225517A1

Автор: Brenner Charles M., Fagan Rebecca L.

Принадлежит: UNIVERSITY OF IOWA RESEARCH FOUNDATION

The invention provides compounds of formula I: 4. The compound of wherein Ris aryl claim 1 , heteroaryl or heterocycle claim 1 , wherein aryl claim 1 , heteroaryl or heterocycle is optionally substituted with one or more Zgroups.8. A method for suppressing cancer cell growth comprising contacting a cancer cell with a compound of formula I as described or a compound of formula II-XI claim 1 , or a salt thereof.9. A method for inhibiting DNMT in a cell claim 1 , comprising contacting the cell in vitro or in vivo with an effective amount of a compound of formula I as described or a compound of formula II-XI or a salt thereof.10. A method for treating cancer in a mammal comprising administering the mammal an effective amount of a compound of formula I as described in or a compound of formula II-XI or a pharmaceutically acceptable salt thereof.12. A method for suppressing cancer cell growth comprising contacting a cancer cell with a compound of formula II-XI as described in or a salt thereof.13. A method for inhibiting DNMT in a cell claim 11 , comprising contacting the cell in vitro or in vivo with an effective amount of a compound of formula II-XI as described in or a salt thereof.14. A method for treating cancer in a mammal comprising administering the mammal an effective amount of a compound of formula II-XI as described in or a pharmaceutically acceptable salt thereof. This application claims priority to U.S. Provisional Application No. 61/603,121 that was filed on Feb. 24, 2012. The entire content of this provisional application is hereby incorporated herein by reference.The invention described herein was made with government support under Contract Number HHSN261200433000C (Subcontract to University of Toledo, Work Assignment 14). The United States Government has certain rights in the invention.There are several isoforms in the DNA methyltransferase family across species, but they all catalyze the transfer of a methyl group (from donor S-adenosyl methionine aka ...

Подробнее

Номер записи: 98

29-08-2013 дата публикации

VIRAL INHIBITOR COMPOSITIONS FOR IN VIVO THERAPEUTIC USE COMPRISING A COMBINATION OF (-) -CARVONE, GERANIOL AND A FURTHER ESSENTIAL OIL COMPONENT

Номер: US20130225676A1

Автор: Coppens Christine

Принадлежит:

The present invention concerns an antiviral composition comprising the following components: R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (−) carvone) and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (+) carvone) and (E)-3,7-dimethylocta-2,6-dien-1-ol (also called trans-geraniol) in combination with at least one more component chosen among essential oils components for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses. 112-. (canceled)13. Composition comprising(−)-Carvone and(+)-Carvone andTrans-Geraniol andat least one more component chosen amongEugenol methylether andLinalooloxide and(cis+trans)-1,2-(+)-Limonene oxide and(+/−)-Isomenthol andEugenol andTrans-Nerolidol and(cis+trans)-Nerolidol andLavendulolin a pharmaceutically effective concentrationfor use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses, said diseases are selected from the group consisting in:(broncho)-pneumonia, 3 day fever exanthema, acute and chronic hepatitis, acute fever, acute gastroenteritis caused by strains such as Desert Shield Lordsdale Mexico Norwalk Hawaii Snow Mountain Southampton virus, acute gastroenteritis caused by strains such as Houston/86 Houston/90 London 29845 Manchester Parkville Sapporo virus, acute hepatitis, acute respiratory distress syndrome, AIDS, Argentine hemorrhagic fever, arthralgia, avian flu, Bolivian hemorrhagic fever, Brazilian hemorrhagic fever, chickenpox, chronic hepatitis, coma, common cold infection, common cold symptoms, congenital infection, conjunctivitis, contagious ecthyma, contagious pustular dermatitis, cornea, cryptic enteric infection, cytomegaloviral mononucleosis, dengue hemorrhagic fever (DHF), dengue shock syndrome (DSS), diarrhea, eczema, eczema herpaticum, encephalitis, encephalopathy, enteritis, ...

Подробнее

Номер записи: 99

29-08-2013 дата публикации

PHARMACEUTICAL COMPOSITIONS OF CURCUMIN

Номер: US20130225689A1

Автор: Goda Chirag Chandrakant, Gogia Ashish Premkumar, Khamar Bakulesh Mafatlal, Khan Imran Ahmad, Laddha Ritu Nitin, Modi Indravadan Ambalal, Patravale Vandana Bharat, Shenoy Dinesh Balkunje, Shrivastava Rajneesh Ramesh

Принадлежит: CADILA PHARMACEUTICALS LIMITED

The present invention relates to stable liquid pharmaceutical compositions of curcumin or its pharmaceutically acceptable salts or its derivatives with higher curcumin concentration and improved bioavailability without the use of buffer and/or molecular aggregation inhibitor(s). In accordance with present invention the curcumin is in the solubilized form to make a stable liquid pharmaceutical composition. 1. A stable pharmaceutical composition comprising:curcumin, oil, solvent, and surfactant wherein the ratio of oil to solvent is about 0.83 to about 10, surfactant to solvent is about 1 to about 60, and surfactant to curcumin is about 3 to 15, with curcumin in the range of about 2 to about 20% w/w with respect to the pharmaceutical composition.2. The pharmaceutical composition as claimed in wherein oil is selected from: fractionated coconut oil claim 1 , caprylic/capric triglyceride or an oil containing fatty acid triglycerides claim 1 , preferably medium chain fatty acid triglycerides isopropyl myristate claim 1 , isopropyl palmitate claim 1 , ethyl linoleate or an oil containing ethyl oleate esters of fatty acids and monovalent alkanols propylene glycol dicaprylate claim 1 , propylene glycol dilaurate or an oil containing propylene glycol di-fatty acid esters claim 1 , and combinations thereof.3. The pharmaceutical composition as claimed in wherein surfactant is selected from polysorbate claim 1 , vitamin E TPGS and cremophor.4. The pharmaceutical composition as claimed in wherein the surfactant is preferably cremophor.5. The pharmaceutical composition as claimed in wherein solvent is selected from glycofurol claim 1 , polyethylene glycol claim 1 , glycerol claim 1 , polypropylene glycol claim 1 , propylene glycol claim 1 , glycerin claim 1 , N-methyl-2-pyrolidone and ethyl alcohol or mixture thereof.6. The solvent pharmaceutical composition as claimed in wherein the solvent is preferably mixture of propylene glycol and ethyl alcohol.7. The pharmaceutical ...

Подробнее

Номер записи: 100